Ginkgo Bioworks (DNA) 10-Q 9 Aug 23 2023 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2023	Jul. 31, 2023
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Entity Registrant Name	GINKGO BIOWORKS HOLDINGS, INC.
Entity Tax Identification Number	87-2652913
Entity Central Index Key	0001830214
Entity Incorporation, State or Country Code	DE
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity File Number	001-40097
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Local Phone Number	422-5362
Entity Address, State or Province	MA
Entity Address, Address Line One	27 Drydock Avenue
Entity Address, Address Line One	8th Floor
Entity Address, City or Town	Boston
Entity Address, Postal Zip Code	02210
City Area Code	877
Warrants, each whole warrant exercisable for one Class A ordinary share, each at an exercise price of $11.50 per share [Member]
Document Information [Line Items]
Trading Symbol	DNA.WS
Title of 12(b) Security	Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share
Security Exchange Name	NYSE
Common Class A
Document Information [Line Items]
Trading Symbol	DNA
Title of 12(b) Security	Class A common stock, par value $0.0001 per share
Security Exchange Name	NYSE
Entity Common Stock, Shares Outstanding		1,600,988,177
Common Class B [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		377,864,805

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 1,105,787	$ 1,315,792
Accounts receivable, net	68,019	80,907
Accounts receivable - related parties	899	1,558
Inventory, net	391	4,364
Prepaid expenses and other current assets	48,357	47,458
Total current assets	1,223,453	1,450,079
Property, plant, and equipment, net	294,244	314,773
Operating lease right-of-use assets	391,430	400,762
Investments	119,944	112,188
Equity method investments	1,120	1,543
Intangible assets, net	105,033	111,041
Goodwill	58,829	60,210
Other non-current assets	97,946	88,725
Total Assets	2,291,999	2,539,321
Current liabilities:
Accounts payable	13,630	10,451
Deferred revenue (includes $6,473 and $10,309 from related parties)	39,223	47,817
Accrued expenses and other current liabilities	110,478	114,694
Total current liabilities	163,331	172,962
Non-current liabilities:
Deferred revenue, net of current portion (includes $132,799 and $131,188 from related parties)	179,903	174,767
Operating lease liabilities, non-current	410,938	413,256
Warrant liabilities	14,146	10,868
Other non-current liabilities	20,096	31,191
Total Liabilities	788,414	803,044
Commitments and contingencies (Note 7)
Shareholders' equity:
Preferred stock, $0.0001 par value; 200,000,000 shares authorized; none issued	0	0
Common stock, $0.0001 par value (Note 6)	196	190
Additional paid-in capital	6,280,632	6,136,378
Accumulated deficit	(4,775,943)	(4,397,659)
Accumulated other comprehensive loss	(1,300)	(2,632)
Total stockholders equity	1,503,585	1,736,277
Total Liabilities and Shareholders' Equity	$ 2,291,999	$ 2,539,321

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Preferred stock par or stated value per share	$ 0.0001	$ 0.0001
Preferred stock shares authorized	200,000	200,000
Deferred revenue (includes $2,672 and $10,309 from related parties)	$ 39,223	$ 47,817
Deferred revenue, net of current portion (includes $131,107 and $131,188 from related parties)	$ 179,903	$ 174,767
Preferred stock shares issued	0	0
Common stock par or stated value per share	$ 0.0001	$ 0.0001
Related party
Deferred revenue (includes $2,672 and $10,309 from related parties)	$ 2,672	$ 10,309
Deferred revenue, net of current portion (includes $131,107 and $131,188 from related parties)	$ 131,107	$ 131,188

Condensed Consolidated Statemen

Condensed Consolidated Statement of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	[1]
Biosecurity revenue:
Total Revenue		$ 80,568	$ 144,618	$ 161,270	$ 313,023
Costs and operating expenses:
Research and development		144,282	290,059	306,921	613,635
General and administrative		102,341	438,427	213,774	873,195
Total operating expenses		264,719	792,397	561,166	1,636,173
Loss from operations		(184,151)	(647,779)	(399,896)	(1,323,150)
Other income (expense):
Interest income, net		14,349	2,264	28,894	2,441
Loss on equity method investments		(67)	(10,166)	(1,516)	(31,053)
Loss on investments		(2,121)	(38,673)	(8,491)	(38,223)
Change in fair value of warrant liabilities		(4,482)	23,509	(3,278)	108,544
Gain on deconsolidation of subsidiary		0	0	0	15,900
Other income, net		3,224	230	6,152	2,149
Total other income (expense), net		10,903	(22,836)	21,761	59,758
Loss before income taxes		(173,248)	(670,615)	(378,135)	(1,263,392)
Income tax expense (benefit)		67	(45)	149	(229)
Net loss		(173,315)	(670,570)	(378,284)	(1,263,163)
Loss attributable to non-controlling interest		0	(1,745)	0	(3,833)
Net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders		$ (173,315)	$ (668,825)	$ (378,284)	$ (1,259,330)
Net loss per share attributable to Ginkgo Bioworks Holdings, Inc. common stockholders:
Basic		$ (0.09)	$ (0.41)	$ (0.2)	$ (0.78)
Diluted		$ (0.09)	$ (0.41)	$ (0.2)	$ (0.78)
Weighted average common shares outstanding
Basic		1,933,437	1,620,704	1,924,251	1,614,138
Diluted		1,933,437	1,620,704	1,924,251	1,614,138
Comprehensive loss:
Net loss		$ (173,315)	$ (670,570)	$ (378,284)	$ (1,263,163)
Other comprehensive income (loss):
Foreign currency translation adjustment		314	(3,141)	1,332	(3,781)
Total other comprehensive income (loss)		314	(3,141)	1,332	(3,781)
Comprehensive loss		(173,001)	(673,711)	(376,952)	(1,266,944)
Product [Member]
Biosecurity revenue:
Total Revenue		10,788	3,887	22,454	17,834
Costs and operating expenses:
Cost of Biosecurity revenue		2,034	2,444	6,575	10,539
Service [Member]
Biosecurity revenue:
Total Revenue		24,497	96,489	59,437	229,459
Costs and operating expenses:
Cost of Biosecurity revenue		16,062	61,467	33,896	138,804
Cell Engineering revenue [Member]
Biosecurity revenue:
Total Revenue	[2]	$ 45,283	$ 44,242	$ 79,379	$ 65,730
[1] As adjusted to reflect the impact of the adoption of Accounting Standards Codification Topic 842, Leases (“ASC 842”) as of January 1, 2022. See Note 1 for a summary of the adjustments. Includes related party revenue of $ 6,507 and $ 7,973 for the three months ended June 30, 2023 and 2022 , respectively, and $ 11,212 and $ 21,501 for the six months ended June 30, 2023 and 2022, respectively.

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Related Party [Member]
Revenues	$ 6,507	$ 7,973	$ 11,212	$ 21,501

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Shareholders' Equity - USD ($) $ in Thousands		Total		Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Noncontrolling Interest [Member]
Beginning balance at Dec. 31, 2021		$ 1,567,379		$ 161	$ 3,804,844	$ (2,297,925)	$ (1,715)	$ 62,014
Beginning balance, Shares at Dec. 31, 2021				1,611,392,000
Issuance of common stock upon exercise or vesting of equity awards, Shares				18,984,000
Issuance of common stock upon exercise or vesting of equity awards		78		$ 2	76
Tax withholdings related to net share settlement of equity awards, Shares				(296,000)
Tax withholdings related to net share settlement of equity awards		(981)			(981)
Issuance of common stock for acquisitions, net of forfeitures, Shares				5,554,000
Issuance of common stock for acquisitions, net of forfeitures		20,128		$ 1	20,127
Stock-based compensation expense		1,276,179			1,273,952			2,227
Foreign currency translation		(3,781)	[1]				(3,781)
Adoption of ASC 842		5,195				5,195
Deconsolidation of subsidiary		(28,783)						(28,783)
Net loss		(1,263,163)	[1]			(1,259,330)		(3,833)
Ending balance at Jun. 30, 2022	[2]	1,572,251		$ 164	5,098,018	(3,552,060)	(5,496)	31,625
Ending balance, Shares at Jun. 30, 2022	[2]			1,635,634,000
Beginning balance at Mar. 31, 2022		1,619,243		$ 162	4,471,418	(2,883,235)	(2,355)	33,253
Beginning balance, Shares at Mar. 31, 2022				1,622,054,000
Issuance of common stock upon exercise or vesting of equity awards, Shares				8,026,000
Issuance of common stock upon exercise or vesting of equity awards		2		$ 1	1
Issuance of common stock for acquisitions, net of forfeitures, Shares				5,554,000
Issuance of common stock for acquisitions, net of forfeitures		20,128		$ 1	20,127
Stock-based compensation expense		606,589			606,472			117
Foreign currency translation		(3,141)					(3,141)
Net loss		(670,570)				(668,825)	0	(1,745)
Ending balance at Jun. 30, 2022	[2]	1,572,251		$ 164	5,098,018	(3,552,060)	(5,496)	$ 31,625
Ending balance, Shares at Jun. 30, 2022	[2]			1,635,634,000
Beginning balance at Dec. 31, 2022		1,736,277		$ 190	6,136,378	(4,397,659)	(2,632)
Beginning balance, Shares at Dec. 31, 2022				1,891,976,000
Issuance of common stock upon exercise or vesting of equity awards, Shares				57,899,000
Issuance of common stock upon exercise or vesting of equity awards		484		$ 6	478
Tax withholdings related to net share settlement of equity awards, Shares				(14,000)
Tax withholdings related to net share settlement of equity awards		(23)			(23)
Issuance of common stock for acquisitions, net of forfeitures, Shares				2,820,000
Issuance of common stock for acquisitions, net of forfeitures		3,581			3,581
Issuance of common stock in exchange for services, Shares				2,023,000
Issuance of common stock in exchange for services		2,500			2,500
Stock-based compensation expense		135,456			135,456
Foreign currency translation		1,332					1,332
Settlement of contingent consideration - restricted stock		2,262			2,262
Net loss		(378,284)				(378,284)
Ending balance at Jun. 30, 2023		1,503,585		$ 196	6,280,632	(4,775,943)	(1,300)
Ending balance, Shares at Jun. 30, 2023				1,954,704,000
Beginning balance at Mar. 31, 2023		1,607,586		$ 194	6,211,634	(4,602,628)	(1,614)
Beginning balance, Shares at Mar. 31, 2023				1,933,880,000
Issuance of common stock upon exercise or vesting of equity awards, Shares				15,995,000
Issuance of common stock upon exercise or vesting of equity awards		472		$ 2	470
Tax withholdings related to net share settlement of equity awards, Shares				(14,000)
Tax withholdings related to net share settlement of equity awards		(23)			(23)
Issuance of common stock for acquisitions, net of forfeitures, Shares				2,820,000
Issuance of common stock for acquisitions, net of forfeitures		3,581			3,581
Issuance of common stock in exchange for services, Shares				2,023,000
Issuance of common stock in exchange for services		2,500			2,500
Stock-based compensation expense		62,470			62,470
Foreign currency translation		314					314
Net loss		(173,315)				(173,315)
Ending balance at Jun. 30, 2023		$ 1,503,585		$ 196	$ 6,280,632	$ (4,775,943)	$ (1,300)
Ending balance, Shares at Jun. 30, 2023				1,954,704,000
[1] As adjusted to reflect the impact of the adoption of Accounting Standards Codification Topic 842, Leases (“ASC 842”) as of January 1, 2022. See Note 1 for a summary of the adjustments. As adjusted to reflect the impact of the adoption of ASC 842 as of January 1, 2022. See Note 1 for a summary of the adjustments.

Condensed Consolidated Statem_4

Condensed Consolidated Statement of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities:
Net loss	$ (378,284)	$ (1,263,163)	[1]
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	36,610	17,968
Stock-based compensation	134,474	1,259,336
Loss on equity method investments	1,516	31,053	[1]
Loss on investments	8,491	38,223	[1]
Change in fair value of warrant liabilities	3,278	(108,544)	[1]
Change in fair value of contingent consideration liability	8,453	300
Gain on deconsolidation of subsidiaries (Note 6)	0	(15,900)	[1]
Impairment loss on assets held for sale	9,001	0
Non-cash customer consideration	(353)	(18,139)
Non-cash lease expense	16,327	7,536
Amortization of finance lease right-of-use assets	569	1,004
Non-cash in-process research and development	3,981	1,162
Other non-cash activity	2,213	502
Changes in operating assets and liabilities:
Accounts receivable ($659 and $1,345 from related parties)	15,397	(38,598)
Prepaid expenses and other current assets	9,538	4,373
Inventory	2,549	(4,740)
Operating lease right-of-use assets	4,096	0
Other non-current assets	(2,426)	(419)
Accounts payable	2,993	10,650
Accrued expenses and other current liabilities	(6,997)	(12,881)
Deferred revenue, current and non-current ($(7,718) and $(14,667) from related parties)	(21,372)	(19,708)
Operating lease liabilities, current and non-current	(13,250)	(5,332)
Other non-current liabilities	(922)	(3,989)
Net cash used in operating activities	(164,118)	(119,306)
Cash flows from investing activities:
Cash acquired in acquisition	0	1,440
Purchase of convertible note	0	(6,500)
Purchases of property and equipment	(32,974)	(13,153)
Proceeds from sale of held for sale assets	2,926	0
Prepayment for marketable equity securities	0	(3,691)
Deconsolidation of subsidiary - cash	0	(28,772)
Other	(590)	(49)
Net cash used in investing activities	(30,638)	(50,648)
Cash flows from financing activities:
Principal payments on finance/capital leases and lease financing obligation	(648)	(609)
Contingent consideration payment	(1,042)	(521)
Other	(579)	(905)
Net cash provided by financing activities	(2,269)	(2,035)
Effect of foreign exchange rates on cash and cash equivalents	(495)	(104)
Net (decrease) increase in cash, cash equivalents and restricted cash	(197,520)	(172,093)
Cash and cash equivalents, beginning of period	1,315,792	1,550,004
Restricted cash, beginning of period	53,789	42,924
Cash, cash equivalents and restricted cash, beginning of period	1,369,581	1,592,928
Cash and cash equivalents, end of period	1,105,787	1,377,152
Restricted cash, end of period	66,274	43,683
Cash, cash equivalents and restricted cash, end of period	1,172,061	$ 1,420,835
Supplemental disclosure of non-cash investing and financing activities:
ROU assets obtained in exchange for new operating lease liabilities upon adoption of ASC 842	0
ROU assets obtained in exchange for new finance lease liabilities upon adoption of ASC 842	0
ROU asset obtained in exchange for new operating lease liabilities	13,649
ROU Asset obtained in exchange for new finance lease liabilities	0
Equity received in related parties	0
Settlement of contingent consideration - restricted stock	$ 2,262
[1] As adjusted to reflect the impact of the adoption of Accounting Standards Codification Topic 842, Leases (“ASC 842”) as of January 1, 2022. See Note 1 for a summary of the adjustments.

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Statement of Cash Flows [Abstract]
Accounts receivable ($659 and $1,345 from related parties)	$ 659	$ 1,345
Deferred revenue, current and non-current ($(7,718) and $(14,667) from related parties)	$ 7,718	$ (14,667)

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	1. Basis of Presentation and Summary of Significant Accounting Policies Business The mission of Ginkgo Bioworks Holdings, Inc. (“Ginkgo” or the “Company”) is to make biology easier to engineer. The Company designs custom cells for customers across multiple markets. Since inception, the Company has devoted its efforts to improving its platform for programming cells to enable customers to leverage biology to create impactful products across a range of industries. The Company’s platform comprises (i) equipment, robotic automation, software, data pipelines and tools, and standard operating procedures for high throughput genetic engineering, fermentation, and analytics (referred to collectively as the “Foundry”), (ii) a library of proprietary genetic assets and associated performance data (referred to collectively as “Codebase”), and (iii) the Company’s team of expert users, developers and operators of the Foundry and Codebase. With a mission to make biology easier to engineer, the Company has recognized the need to invest in biosecurity as a key component of its platform. The Company’s biosecurity and public health unit, Concentric by Ginkgo, is building a global infrastructure for biosecurity to empower governments, communities, and public health leaders to prevent, detect and respond to a wide variety of biological threats. Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in conformity with the rules and regulations of the Securities and Exchange Commission and generally accepted accounting principles in the United States (“GAAP”) for interim financial reporting. Accordingly, certain detailed disclosures which would normally be included with annual financial statements have been omitted. In the opinion of management, all normal recurring adjustments necessary for a fair presentation have been made. These condensed consolidated financial statements should be read in conjunction with the Company's 2022 Annual Report on Form 10-K. Interim results are not necessarily indicative of results for a full year. Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries, majority owned subsidiaries and variable interest entities if the Company is the primary beneficiary. All intercompany accounts and transactions have been eliminated. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and the disclosure of contingent liabilities in the condensed consolidated financial statements. Estimates used in the preparation of these condensed consolidated financial statements include, among others, revenue recognition, stock-based compensation, the fair value of assets acquired and liabilities assumed in a business combination, the fair value of non-cash consideration received from customers, the fair value of certain notes receivable, the fair value of certain investments including equity method investments, the fair value of warrant liabilities, the allocation of equity method investment losses under the hypothetical liquidation at book value (“HLBV”) method, the incremental borrowing rate used in determining lease liabilities, allowance for credit losses, accrued expenses and income taxes. The Company bases its estimates on historical experience and other market-specific or relevant assumptions that it believes to be reasonable under the circumstances. Reported amounts and disclosures reflect the overall economic conditions that management believes are most likely to occur, and the anticipated measures management intends to take. Actual results could differ materially from those estimates. All revisions to accounting estimates are recognized in the period in which the estimates are revised. Significant Accounting Policies There have been no new or material changes to the Company’s significant accounting policies during the six months ended June 30, 2023 as compared to the significant accounting policies described in Note 2 to the Company's 2022 consolidated financial statements included in the 2022 Annual Report on Form 10-K. Retrospective Application of a Change in Accounting Principle The Company adopted Accounting Standards Update No. 2016-02, Leases (“ASC 842”), which supersedes the guidance in Accounting Standards Codification Topic 840, Leases (“ASC 840”), effective January 1, 2022. As the Company elected the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the Jumpstart Our Business Startups Act of 2012, ASC 842 was adopted in connection with the preparation of the Company’s annual consolidated financial statements as of and for the year ended December 31, 2022. As such, the comparative information for the three and six months ended June 30, 2022 has been adjusted herein to reflect the impact of the adoption of ASC 842 as of January 1, 2022. Select line items from the condensed consolidated statement of operations and comprehensive loss reflecting the adoption of ASC 842 are as follows (in thousands): Three Months Ended June 30, 2022 Six Months Ended June 30, 2022 As Previously Reported Adjustments As Adjusted As Previously Reported Adjustments As Adjusted Costs and operating expenses: Research and development $ 289,188 $ 871 $ 290,059 $ 611,908 $ 1,727 $ 613,635 Total operating expenses 791,526 871 792,397 1,634,446 1,727 1,636,173 Loss from operations ( 646,908 ) ( 871 ) ( 647,779 ) ( 1,321,423 ) ( 1,727 ) ( 1,323,150 ) Other income (expense): Interest income, net 1,674 590 2,264 1,277 1,164 2,441 Other income (expense), net ( 51 ) 281 230 1,586 563 2,149 Total other income (expense), net ( 23,707 ) 871 ( 22,836 ) 58,031 1,727 59,758 Select line items from the condensed consolidated statements of stockholders’ equity reflecting the adoption of ASC 842 are as follows (in thousands): As of June 30, 2022 As Previously Reported Adjustments As Adjusted Accumulated deficit $ ( 3,557,255 ) $ 5,195 $ ( 3,552,060 ) Total stockholders' equity 1,567,056 5,195 1,572,251 Select line items from the condensed consolidated statements of cash flows reflecting the adoption of ASC 842 are as follows (in thousands): Six Months Ended June 30, 2022 As Previously Reported Adjustments As Adjusted Cash flows from operating activities: Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization $ 19,096 $ ( 1,128 ) $ 17,968 Amortization of finance lease right-of-use assets — 1,004 1,004 Non-cash lease expense — 7,536 7,536 Changes in operating assets and liabilities: Prepaid expenses and other current assets 4,973 ( 600 ) 4,373 Accrued expenses and other current liabilities ( 12,758 ) ( 123 ) ( 12,881 ) Operating lease liabilities, current and non-current — ( 5,332 ) ( 5,332 ) Deferred rent, non-current 1,468 ( 1,468 ) — Cash flows from financing activities: Principal payments on finance leases — ( 609 ) ( 609 ) Principal payments on capital leases and lease financing obligation ( 720 ) 720 — Recently Issued Accounting Pronouncements There were no new recently issued accounting pronouncements that are of significance or potential significance to the Company from those disclosed herein and within Note 2 to the Company's 2022 consolidated financial statements included in the 2022 Annual Report on Form 10-K.

Business Combination

Business Combination	6 Months Ended
	Jun. 30, 2023
Business Combinations [Abstract]
Business Combination	2. Business Combination On April 1, 2022, the Company acquired all of the outstanding equity interests of FGen AG (“FGen”), a company organized under the laws of Switzerland that specializes in strain development and optimization and has developed an ultra-high-throughput screening platform. The Company accounted for the transaction as a business combination under ASC 805, Business Combinations . The consideration paid was comprised of common stock and contingent consideration as follows (in thousands): Fair value of Class A common stock $ 17,015 Fair value of contingent consideration - restricted stock 3,842 Fair value of contingent consideration - milestones 8,464 Total FGen consideration $ 29,321 The Company issued 5,749,957 shares of its Class A common stock on the acquisition date comprised of 4,051,107 unrestricted shares valued at $ 17.0 million based on the closing market price of $ 4.20 per share and 1,698,850 restricted shares classified as contingent consideration and subject to vesting conditions. Of the restricted shares, 584,246 shares were subsequently forfeited during the quarter ended June 30, 2022 when the contingency related to the filing of a registration statement was resolved. The Company incurred $ 1.7 million of acquisition-related costs which were included in general and administrative expenses in the consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2022. The following table presents the final allocation of the purchase price to the assets acquired and liabilities assumed as of the acquisition date (in thousands): Preliminary Allocation Measurement Period Adjustment (3) Final Allocation Cash and cash equivalents $ 1,430 $ $ 1,430 Accounts receivable 144 — 144 Other non-current assets 10 — 10 Property and equipment 146 ( 112 ) 34 Intangible assets (1) 21,100 — 21,100 Goodwill (2) 11,001 ( 386 ) 10,615 Accounts payable and accrued expenses ( 29 ) — ( 29 ) Deferred revenue ( 104 ) — ( 104 ) Deferred tax liability ( 4,377 ) 498 ( 3,879 ) Net assets acquired $ 29,321 $ — $ 29,321 (1) Estimated useful life of 15 years . (2) Non-deductible for tax purposes. (3) Represents adjustments related to tangible assets acquired and estimated tax liabilities with a corresponding net decrease to goodwill.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	3. Fair Value Measurements The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis (in thousands): As of June 30, 2023 Classification Total Level 1 Level 2 Level 3 Assets: Money market funds Cash and cash equivalents $ 1,066,056 $ 1,066,056 $ — $ — Synlogic, Inc. warrants (1) Investments 1,095 — 1,095 — Marketable equity securities Investments 19,876 19,876 — — Loan receivable Prepaid expenses and other current assets 358 — — 358 Notes receivable Other non-current assets 38,950 — 30,000 8,950 Total assets $ 1,126,335 $ 1,085,932 $ 31,095 $ 9,308 Liabilities: Public Warrants Warrant liabilities $ 8,970 $ 8,970 $ — $ — Private Placement Warrants (3) Warrant liabilities 5,176 — 141 5,035 Contingent consideration Accrued expenses and other current liabilities 22,945 — — 22,945 Contingent consideration Other non-current liabilities 7,617 — — 7,617 Total liabilities $ 44,708 $ 8,970 $ 141 $ 35,597 As of December 31, 2022 Classification Total Level 1 Level 2 Level 3 Assets: Money market funds Cash and cash equivalents $ 1,089,026 $ 1,089,026 $ — $ — Synlogic, Inc. warrants (1) Investments 1,937 — 1,937 — Marketable equity securities (2) Investments 25,714 21,312 4,402 — Notes receivable Other non-current assets 37,660 — 30,000 7,660 Total assets $ 1,154,337 $ 1,110,338 $ 36,339 $ 7,660 Liabilities: Public Warrants Warrant liabilities $ 6,900 $ 6,900 $ — $ — Private Placement Warrants (3) Warrant liabilities 3,968 — 108 3,860 Contingent consideration Accrued expenses and other current liabilities 6,378 — — 6,378 Contingent consideration Other non-current liabilities 18,095 — — 18,095 Total liabilities $ 35,341 $ 6,900 $ 108 $ 28,333 (1) The fair value of Synlogic, Inc. warrants is calculated as the quoted price of the underlying common stock, less the unpaid exercise price of the warrants. (2) Marketable equity securities classified as Level 2 reflect a discount for lack of marketability due to regulatory sales restrictions. (3) The fair value of Private Placement Warrants classified as Level 2 is equivalent to that of Public Warrants as the transfer of Private Placement Warrants to anyone other than the initial purchasers or any of their permitted transferees results in the Private Placement Warrants having substantially the same terms as the Public Warrants. Transfers to/from Levels 1, 2 and 3 are recognized at the end of the reporting period in which a change in valuation technique or methodology occurs. Transfers from Level 2 to Level 1 during the six months ended June 30, 2022 were due to a lapse on regulatory sales restrictions on marketable equity securities. There were no other transfers to/from Levels 1, 2, or 3 during the six months ended June 30, 2023 and 2022. Notes Receivable The Company has elected the fair value option under ASC 825, Financial Instruments , to account for its notes receivable. Notes receivable accounted for under the fair value option are marked to market as of each balance sheet date with changes in fair value recorded in other income, net in the condensed consolidated statements of operations and comprehensive loss. As of June 30, 2023 and December 31, 2022, notes receivable measured at fair value on a recurring basis primarily consisted of a $ 30.0 million senior secured note (“Senior Secured Note”) purchased from Bolt Threads, Inc. and a series of convertible promissory notes issued by customers as payment for Cell Engineering services. The Company used the yield method to value the Senior Secured Note. Under this method, the estimated future cash flows, consisting of principal and interest payments, are discounted to present value using an applicable market yield or discount rate. Increases or decreases in the market yield or discount rate would result in a decrease or increase, respectively, in the fair value measurement. The market yield is determined using a corporate bond yield curve corresponding to the credit rating category of the issuer. The fair value of the Senior Secured Note is based on observable market inputs, which represents a Level 2 measurement within the fair value hierarchy. The Company used a scenario-based method to value the series of convertible promissory notes from customers. Under the scenario-based method, future cash flows are evaluated under a qualified financing, maturity and dissolution scenarios, probability-weighted, and discounted to present value. The significant unobservable (Level 3) inputs used in the fair value measurement as of June 30, 2023 were scenario probabilities of 15 % to 55 %, a discount rate of 17 % and estimated time to event date of one to two years . The significant unobservable (Level 3) inputs used in the fair value measurement as of December 31, 2022 were scenario probabilities of 15 % to 55 %, a discount rate of 12.5 % and estimated time to event date of one to three years . Significant changes in these inputs could have resulted in a significantly lower or higher fair value measurement. As of June 30, 2023 , the convertible promissory notes had an unpaid principal balance of $ 11.7 million and a fair value of $ 9.3 million. As of December 31, 2022 , the convertible promissory notes had an unpaid principal balance of $ 7.5 million and a fair value of $ 7.7 million. The following table provides a reconciliation of notes and loans receivable measured at fair value using Level 3 significant unobservable inputs for the six months ended June 30 (in thousands): 2023 2022 Balance at January 1, $ 7,660 $ 11,559 Additions 3,137 — Change in fair value ( 1,489 ) ( 292 ) Balance at June 30, $ 9,308 $ 11,267 Warrant Liabilities In connection with the Company's merger with Soaring Eagle Acquisition Corp. (“SRNG”) on September 16, 2021, the Company assumed 34.5 million publicly-traded warrants (“Public Warrants”) and 17.3 million private placement warrants (the “Private Placement Warrants”) previously issued in connection with SRNG’s initial public offering. The fair value of the Public Warrants is based on the observable quoted price of such warrants on the New York Stock Exchange. The fair value of the Private Placement Warrants is estimated using the Black-Scholes option pricing model, which is considered to be a Level 3 fair value measurement. The primary unobservable input used in the valuation of the Private Placement Warrants is expected stock-price volatility. The Company estimated the volatility of its Private Placement Warrants using a Monte-Carlo simulation of the redeemable Public Warrants that assumes optimal exercise of the Company's redemption option at the earliest possible date. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend yield is based on the historical rate, which the Company anticipates remaining at zero. The following table provides quantitative information regarding Level 3 inputs used in the recurring valuation of the Private Placement Warrants as of their measurement dates: June 30, 2023 December 31, 2022 Exercise price $ 11.50 $ 11.50 Stock price $ 1.86 $ 1.69 Volatility 79.0 % 71.5 % Term (in years) 3.21 3.71 Risk-free interest rate 4.49 % 4.11 % The following table provides a reconciliation of the Private Placement Warrants measured at fair value using Level 3 significant unobservable inputs for the six months ended June 30 (in thousands): 2023 2022 Balance at January 1, $ 3,860 $ 58,558 Change in fair value 1,175 ( 49,549 ) Balance at June 30, $ 5,035 $ 9,009 Contingent Consideration In connection with the acquisition of FGen in April 2022, the Company is required to make contingent earnout payments up to $ 20.0 mi llion primarily related to the successful integration and deployment of the FGen technology across the Company's programs. In connection with the acquisition of Dutch DNA Biotech B.V. (“Dutch DNA”) in July 2021, the Company is required to make contingent earnout payments up to a maximum of $ 20.0 million payable upon the achievement of certain technical and commercial milestones by Dutch DNA pursuant to a Technical Development Agreement executed between the Company and Dutch DNA prior to the close of the acquisition. In connection with the acquisition of Circularis Biotechnologies, Inc., (“Circularis”) in October 2022, the Company is required to make contingent earnout payments up to a maximum of $ 40.0 million payable primarily upon the achievement of certain clinical trial milestones over a five-year period. In connection with the acquisition of Altar SAS (“Altar”) in October 2022, the Company is required to make contingent earnout payments up to $ 2.5 million upon the successful transfer of the Altar technology to Ginkgo's sites in the U.S. The Company also issued restricted stock related to acquisitions that is subject to vesting conditions and is classified as contingent consideration liability. The fair value of contingent consideration related to restricted stock was estimated using the quoted price of Ginkgo's Class A common stock, an estimate of the number of shares expected to vest, probability of vesting, and a discount rate. The fair value of contingent consideration related to earnout payments from acquisitions was estimated using unobservable (Level 3) inputs as illustrated in the table below. Material increases or decreases in these inputs could result in a higher or lower fair value measurement. Changes in the fair value of contingent consideration are recorded in general and administrative expense in the condensed consolidated statements of operations and comprehensive loss. The Company can settle all contingent consideration liabilities, other than those related to the Dutch DNA acquisition, in cash or shares of Class A common stock at the Company’s election. During the six months ended June 30, 2023 , the Company settled $ 3.8 million in contingent consideration liabilities through payment of $ 1.5 million in cash and vesting of 1.2 million shares of restricted stock, with a value of $ 2.3 million. Of that amount, $ 1.4 million related to the Circularis asset acquisition was recorded as an increase to the acquired intangible asset with an offset to additional paid-in-capital as the contingent consideration liability was deemed not probable until the filing of a registration statement. The following table provides quantitative information regarding Level 3 inputs used in the fair value measurements of contingent consideration liabilities as of the periods presented: June 30, 2023 December 31, 2022 Contingent Consideration Liability Valuation Technique Unobservable Input Range Range Earnout payments (FGen, Dutch DNA, Circularis and Altar acquisitions) Probability-weighted present value Probability of payment 1 % - 95 % 2 % - 100 % Discount rate 13.5 % - 14.6 % 12.2 % - 13.1 % Earnout payments (Dutch DNA acquisition) Discounted cash flow Projected years of payments 2025 - 2028 2025 - 2028 Discount rate 11.5 % 12.0 % The following table provides a reconciliation of the contingent consideration measured at fair value using Level 3 significant unobservable inputs for the six months ended June 30 (in thousands): 2023 2022 Balance at January 1, $ 24,473 $ 8,467 Additions — 12,306 Change in fair value 8,453 300 Settlements and payments ( 2,364 ) ( 2,644 ) Balance at June 30, $ 30,562 $ 18,429 Nonrecurring Fair Value Measurements The Company measures the fair value of certain assets, including investments in privately held companies without readily determinable fair values, on a nonrecurring basis. These assets are evaluated for impairment when events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. These nonrecurring fair value measurements are considered to be Level 3 in the fair value hierarchy. During the first half of 2023, the Company received $ 11.0 million in Simple Agreement for Future Equity (“SAFEs”) from customers as prepayment for Cell Engineering services. The Company used a scenario-based method to value the SAFEs at contract inception, which resulted in a total fair value of $ 4.5 million . Under the scenario-based method, future cash flows were evaluated under qualified financing and dissolution scenarios with partial recovery and no recovery in dissolution. The cash flows under each scenario were probability-weighted and discounted to present value. The significant unobservable inputs used in the fair value measurement were scenario probabilities of 20 % to 60 %, a discount rate of 14 % and estimated time to event date of one to two years. During the six months ended June 30, 2023 , the Company recorded a $ 1.8 million impairment loss related to a SAFE to write-down its carrying amount to its estimated fair value. The fair value measurement of the impairment loss was determined using the scenario-based method, whereby dissolution scenarios with partial recovery and no recovery were probability weighted 15 % and 85 %, respectively, and discounted to present value using a discount rate of 14 %. Additionally, the Company recorded an impairment loss related to certain equipment that met the asset held-for-sale criteria. Refer to Note 6 for additional detail.

Investments and Equity Method I

Investments and Equity Method Investments	6 Months Ended
	Jun. 30, 2023
Equity Method Investments and Joint Ventures [Abstract]
Investments and Equity Method Investments	4. Investments and Equity Method Investments The Company partners with other investors to form business ventures, including Motif FoodWorks, Inc. (“Motif”), Allonnia, LLC (“Allonnia”), Arcaea, LLC (“Arcaea”), Verb Biotics, LLC (“Verb”), BiomEdit, LLC (“BiomEdit”) and Ayana Bio, LLC (“Ayana”) (collectively “Platform Ventures”). The Company also partners with existing entities, including Genomatica, Inc. (“Genomatica”) and Synlogic, Inc. (“Synlogic”) (collectively, “Legacy Structured Partnerships”) with complementary assets for high potential synthetic biology applications. The Company holds equity interests in these Platform Ventures and Structured Partnerships. The Company also holds equity interests in other public and private companies as a result of entering into collaboration and license revenue arrangements with these entities. The Company accounts for its investments in Platform Ventures under the equity method. The Company's marketable equity securities consist of Synlogic common stock, Synlogic warrants and the shares of common stock of other publicly traded companies. Marketable equity securities are measured at fair value with changes in fair value recorded in other income (expense) in the condensed consolidated statements of operations and comprehensive loss. The Company’s non-marketable equity securities consist of preferred stock of Genomatica and preferred and common stock of other privately held companies without readily determinable fair values. Non-marketable equity securities are initially recorded using the measurement alternative at cost and subsequently adjusted for any impairment and observable price changes in orderly transactions for the identical or a similar security of the same issuer. During the three months ended June 30, 2022, the Company recorded a $ 10.1 million impairment charge, included as a component of loss on investments in the condensed consolidated statements of operations and comprehensive loss, due to a decline in the fair value of the Company's investment in Genomatica preferred stock. There were no impairments recorded or adjustments from observable price changes related to non-marketable equity securities during the three or six months ended June 30, 2023. The Company also holds investments in early-stage synthetic biology product companies via SAFEs. The Company enters into SAFE agreements in conjunction with a revenue contract with a customer under which the Company grants the customer a prepaid Cell Engineering services credit equal to the principal amount of the SAFE (the “Purchase Amount”), which may be used and drawn down as payment for the Company’s research and development services. The SAFEs will automatically convert into shares of preferred stock equal to the Purchase Amount divided by the discount price, which is calculated as the price per share sold in a qualified equity financing multiplied by a discount rate. The SAFEs also provide the Company with the right to future equity of the entity in a liquidation scenario or the cash-out amount in liquidation and dissolution scenarios or at the election of the SAFE issuer prior to an agreed outside date. The Company initially records SAFEs at fair value (see Note 3) and adjusts the carrying amount of the instrument at each reporting period for any impairment, plus or minus changes resulting from observable price changes in orderly transactions for an identical or similar instrument of the same issuer. During the six months ended June 30, 2023 , the Company recorded a $ 1.8 million impairment charge related to SAFEs, included as a component of loss on investments in the condensed consolidated statements of operations and comprehensive loss. There was no impairment recorded during the three or six months ended June 30, 2022 and no adjustments from observable price changes during any of the periods presented. Investments and equity method investments consisted of the following (in thousands): As of June 30, As of December 31, 2023 2022 Investments: Genomatica, Inc. preferred stock $ 44,885 $ 44,885 Synlogic, Inc. common stock 2,727 4,819 Synlogic, Inc. warrants 1,095 1,937 Marketable equity securities 17,149 20,895 Non-marketable equity securities 29,259 17,544 SAFEs 24,829 22,108 Total $ 119,944 $ 112,188 Equity method investments (1) : BiomEdit, LLC $ — $ 369 Other 1,120 1,174 Total $ 1,120 $ 1,543 (1) Equity method investments in Platform Ventures with a carrying value of zero as of June 30, 2023 and December 31, 2022 were excluded from the table. Losses on investments and equity method investments consisted of the following (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Loss on investments: Synlogic, Inc. common stock $ ( 1,281 ) $ ( 7,926 ) $ ( 2,092 ) $ ( 8,053 ) Synlogic, Inc. warrants ( 514 ) ( 3,185 ) ( 841 ) ( 3,236 ) Genomatica, Inc. — ( 10,115 ) — ( 10,115 ) Marketable equity securities ( 326 ) ( 17,447 ) ( 3,747 ) ( 16,819 ) SAFEs — — ( 1,811 ) — Total $ ( 2,121 ) $ ( 38,673 ) $ ( 8,491 ) $ ( 38,223 ) Loss on equity method investments: Joyn Bio, LLC $ — $ ( 5,424 ) $ — $ ( 10,411 ) Verb Biotics, LLC — — — ( 15,900 ) BiomEdit, LLC — ( 4,552 ) ( 1,462 ) ( 4,552 ) Other ( 67 ) ( 190 ) ( 54 ) ( 190 ) Total $ ( 67 ) $ ( 10,166 ) $ ( 1,516 ) $ ( 31,053 )

Variable Interest Entities

Variable Interest Entities	6 Months Ended
	Jun. 30, 2023
Variable Interest Entity, Measure of Activity [Abstract]
Variable Interest Entities	5. Variable Interest Entities Consolidated Variable Interest Entity The Company consolidated Cooksonia, LLC (“Cooksonia”), a variable interest entity (“VIE”) formed by the Company and certain other investors for the purposes of holding the Company’s investment in the Joyn Bio, LLC (“Joyn Bio”) joint venture, prior to the joint venture's termination in the fourth quarter of 2022. The Company concluded that it held a variable interest in and was the primary beneficiary of Cooksonia as it controlled the most significant activities of Cooksonia by controlling 100 % of the board of directors of Cooksonia and held a controlling financial interest in Cooksonia. Unconsolidated Variable Interest Entities During the first quarter of 2022, the Company deconsolidated Verb following the hiring of a new chief executive officer of Verb who was not an affiliate, related party or agent of Ginkgo. The chief executive officer was also appointed to Verb's Joint Steering Committee and board of directors. As a result, the Company no longer had substantive control of the board of directors or the Joint Steering Committee. Accordingly, the Company concluded that it was no longer the primary beneficiary of Verb as it no longer controlled the most significant activities of the entity. As a result of this change in the primary beneficiary determination, the Company deconsolidated the entity and recorded a gain on deconsolidation of $ 15.9 million equal to the fair value of the retained interest as of the deconsolidation date. The fair value of the retained interest was determined using the option pricing method. The option pricing method used a Black-Scholes methodology to infer the total equity value based on the pricing of the Series A preferred unit financing given the proximity of the deconsolidation event to the financing. As of June 30, 2023 and December 31, 2022, the Company has concluded that its investments in Motif, Allonnia, Genomatica, Arcaea, BiomEdit, Verb and Ayana (collectively, the “Unconsolidated VIEs”) represent variable interests and that these entities are VIEs. Although the Company may have board representation and is involved in the ongoing development activities of the entities via its participation on the JSC, the Company has concluded that it is not the primary beneficiary of these entities. This conclusion is supported by the fact that: (i) the Company does not control the board of directors of any of the Unconsolidated VIEs, and no voting or consent agreements exist between the Company and other members of each respective board of directors or other investors, (ii) the holders of preferred security interests in the Unconsolidated VIEs hold certain rights that require their consent prior to taking certain actions, which include certain significant operating and financing decisions, and (iii) the Company’s representation on the JSC of each respective entity does not give it control over the development activities of any of the Unconsolidated VIEs, as all JSC decisions are made by consensus and there are no agreements in place that would require any of the entities to vote in alignment with the Company. As the Company’s involvement in the Unconsolidated VIEs does not give it the power to control the decisions with respect to their development or other activities, which are their most significant activities, the Company has concluded that it is not the primary beneficiary of the Unconsolidated VIEs. Additionally, the Company holds equity interests in certain privately-held companies that are not consolidated as the Company is not the primary beneficiary. As of June 30, 2023 and December 31, 2022, the maximum risk of loss related to the Company’s unconsolidated VIEs was limited to the carrying value of its investments in such entities. Refer to Note 4 for additional details on the Company’s investments and equity method investments.

Supplemental Financial Informat

Supplemental Financial Information	6 Months Ended
	Jun. 30, 2023
Supplemental Financial Statement Information [Abstract]
Supplemental Balance Sheet Information	6. Supplemental Financial Information Cash, Cash Equivalents and Restricted Cash The reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheet to the totals shown within the condensed consolidated statement of cash flows is as follows (in thousands): As of June 30, 2023 2022 Cash and cash equivalents $ 1,105,787 $ 1,377,152 Restricted cash included in prepaid expenses and other current assets (1) 22,483 4,239 Restricted cash included in other non-current assets (1) 43,791 39,444 Total cash, cash equivalents and restricted cash $ 1,172,061 $ 1,420,835 (1) I ncludes cash balances collateralizing letters of credit associated with the Company’s facility leases and a customer prepayment requiring segregation and restrictions in its use in accordance with the customer agreement. Inventory, net Inventory, net consisted of the following (in thousands): As of June 30, As of December 31, 2023 2022 Finished goods $ 4,435 $ 6,556 Raw materials 905 1,590 Less: inventory reserve ( 4,949 ) ( 3,782 ) Inventory, net $ 391 $ 4,364 Property, Plant, and Equipment, net Property, plant, and equipment, net consisted of the following (in thousands): As of June 30, As of December 31, 2023 2022 Lab equipment $ 180,025 $ 183,292 Leasehold improvements 136,197 125,307 Buildings and facilities 46,927 46,019 Construction in progress 19,831 23,426 Computer equipment and software 15,322 15,219 Furniture and fixtures 8,352 8,206 Land 6,060 6,060 Total property, plant, and equipment 412,714 407,529 Less: Accumulated depreciation and amortization ( 118,470 ) ( 92,756 ) Property, plant, and equipment, net $ 294,244 $ 314,773 During the three months ended June 30, 2023, the Company identified certain lab equipment acquired as part of the Zymergen, Inc. (“Zymergen”) acquisition that met the asset held-for-sale criteria and were reclassified as assets held-for-sale in the condensed consolidated balance sheet. The aggregate net book value of the equipm ent of $ 14.9 million was written down to fair value less cost to sell, resulting in an impairment loss of $ 9.0 million in the three and six months ended June 30, 2023, included in general and administrative expense in the condensed consolidated statement of operations and comprehensive loss. The fair value measurement relating to the impairment loss was based on the executed sales agreement and represents a Level 2 input within the fair value hierarchy. As of June 30, 2023, the Company had $ 4.2 million of lab equipment, net of accumulated depreciation, classified as held for sale in prepaid expenses and other current assets in the accompanying condensed consolidated balance sheet. The sale is expected to be completed by the end of 2023. Capitalization The following table presents the Company’s authorized, issued, and outstanding common stock as of the dates indicated (in thousands): Authorized Issued Outstanding Common stock as of June 30, 2023: Class A 10,500,000 1,595,167 1,478,611 Class B 4,500,000 378,273 356,093 Class C 800,000 120,000 120,000 15,800,000 2,093,440 1,954,704 Common stock as of December 31, 2022: Class A 10,500,000 1,448,234 1,337,499 Class B 4,500,000 383,649 354,477 Class C 800,000 200,000 200,000 15,800,000 2,031,883 1,891,976 On April 3, 2023, the Company issued 2.8 million shares of its Class A common stock as purchase consideration for the acquisition of StrideBio, Inc. (“StrideBio”) (see Note 8). On May 9, 2023, the Company issued 2.0 million shares of its Class A common stock, valued at approximately $ 2.5 million, as settlement for employee retention payments associated with the FGen acquisition. Refer to Note 9, Stock-Based Compensation, for shares of common stock issued in relation to the Company’s equity incentive plans. Changes in the number of shares of Class C common stock issued and outstanding represent an exchange of Class C common stock for the same number of shares of Class A common stock pursuant to a stockholder exchange agreement. Supplemental cash flow information The following table presents non-cash investing and financing activities (in thousands): Six Months Ended June 30, 2023 2022 (as adjusted)* Supplemental disclosure of non-cash investing and financing activities: ROU Asset obtained in exchange for new operating lease liabilities upon adoption of ASC 842 $ — $ 147,744 ROU Asset obtained in exchange for new finance lease liabilities upon adoption of ASC 842 — 3,397 ROU Asset obtained in exchange for new operating lease liabilities 13,649 28,000 ROU Asset obtained in exchange for new finance lease liabilities — 1,096 Purchases of property and equipment included in accounts payable and accrued expenses 2,324 6,741 Equity received in related parties — 8,873 Convertible financial instruments received for Cell Engineering services 5,595 11,939 Equity securities and warrants received for Cell Engineering services 12,493 3,423 Settlement of contingent consideration - restricted stock 2,262 — Common stock issued for business and asset acquisitions 3,581 17,015 Contingent consideration for business acquisition — 12,306 * As adjusted to reflect the impact of the adoption of ASC 842 as of January 1, 2022. See Note 1 for a summary of the adjustments.

Goodwill and Intangible Assets,

Goodwill and Intangible Assets, net	6 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets, net	7. Goodwill and Intangible Assets, net All goodwill is allocated to the Cell Engineering reporting unit and segment identified in Note 11. Changes in the carrying amount of goodwill consisted of the following (in thousands): Balance as of December 31, 2022 $ 60,210 Impact of foreign currency translation 592 Measurement period adjustments ( 1,973 ) Balance as of June 30, 2023 $ 58,829 During the six months ended June 30, 2023 , the Company recognized a measurement period adjustment related to the Zymergen acquisition, which resulted in a decrease to goodwill of $ 2.2 million, an increase to accounts receivable of $ 1.8 million, and a decrease to accrued expenses and other current liabilities of $ 0.4 million. The adjustment was a result of updated information about facts and circumstances that existed at the acquisition date regarding the collectability of an acquired accounts receivable and accrued expenses under a collaboration agreement. Additionally, $ 0.2 million was added to goodwill related to the Altar SAS acquisition. Intangible assets, net consisted of the following (in thousands): Gross (1) Accumulated (1) Net Weighted Average June 30, 2023: Developed technology $ 118,134 $ ( 16,717 ) $ 101,417 9.0 Database 3,700 ( 371 ) 3,329 6.3 Customer relationships 380 ( 166 ) 214 1.1 Assembled workforce 190 ( 117 ) 73 0.5 Total intangible assets $ 122,404 $ ( 17,371 ) $ 105,033 December 31, 2022: Developed technology $ 115,824 $ ( 8,825 ) $ 106,999 9.4 Database 3,700 ( 107 ) 3,593 6.8 Customer relationships 380 ( 71 ) 309 1.6 Assembled workforce 190 ( 50 ) 140 1.0 Total intangible assets $ 120,094 $ ( 9,053 ) $ 111,041 (1) Gross carrying value and accumulated amortization include the impact of cumulative foreign currency translation adjustments. Amortization expense was $ 4.0 million and $ 0.8 million for the three months ended June 30, 2023 and 2022 , respectively, and $ 8.3 million and $ 1.3 million for the six months ended June 30, 2023 and 2022, respectively. As of June 30, 2023, estimated future amortization expense for identifiable intangible assets is as follows (in thousands): Remainder of 2023 $ 7,911 2024 15,630 2025 15,505 2026 15,505 2027 12,431 Thereafter 38,051 Total $ 105,033

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies Purchase Obligations On March 31, 2022, the Company entered into a four-year supply agreement with Twist Bioscience Corporation for the purchase of diverse products including synthetic DNA. The agreement obligates the Company to a minimum spend over a four-year term (with each annual year defined as April 1 to March 31). The remaining three year term minimum annual commitments are: year 2, $ 13.0 million; year 3, $ 16.0 million; and year 4, $ 19.0 million. Contingent Consideration Related to Asset Acquisitions On April 5, 2023, the Company entered into an Asset Purchase Agreement (“APA”) with StrideBio to acquire StrideBio's adeno-associated virus capsid discovery and engineering platform assets, with a secondary close contingent upon the transfer of certain additional in-license agreements to Ginkgo. The Company accounted for the transaction as an asset acquisition as substantially all of the fair value of the assets acquired is concentrated in a single identifiable asset. The fair value of the consideration transferred totaled $ 4.0 million and consisted of 2.8 million shares of Ginkgo's Class A common stock valued at $ 3.6 million and a $ 0.4 million contingent holdback, all of which was expensed as in-process research and development during the three months ended June 30, 2023, as the assets have no alternative future use. Additional consideration of $ 7.5 million is payable on the secondary closing date in cash or shares of Class A common stock at the Company’s election. The APA also provides for royalty payments of up to $ 17.5 million payable in cash or shares of Class A common stock at the Company's election until the earlier of the tenth anniversary date of the initial closing and the date on which the aggregate amount of the royalty payments equals the amount cap. The royalties are calculated based on 10 % of the net licensing revenue and 40 % of all consideration received for a license or sale of a product incorporating the acquired platform assets. No amounts for the royalty payments have been recorded during the three or six months ended June 30, 2023. The Company routinely acquires rights to intellectual property that may provide for payment of future contingent consideration, including royalties, should revenue be generated from the use of such. Legal Proceedings From time to time, the Company may in the ordinary course of business be named as a defendant in lawsuits, indemnity claims and other legal proceedings. Except as described below, the Company does not believe any pending litigation to be material, or that the outcome of any such pending litigation, in management’s judgment based on information currently available, would have a material adverse effect on the Company’s results of operations, cash flows or financial condition. On August 4, 2021, a putative securities class action was filed on behalf of purchasers of the common stock of Zymergen, pursuant to or traceable to the registration statement for Zymergen’s initial public offering (“IPO”). The action is pending in the United States District Court for the Northern District of California, and is captioned Wang v. Zymergen Inc., et al., Case No. 3:21-cv-06028-VC. The action alleges violations of Sections 11 and 15 of the Securities Act of 1933, as amended (the “Securities Act”) in connection with Zymergen’s IPO, names Zymergen, certain of its former officers and directors, and its IPO underwriters as defendants and seeks damages in an unspecified amount, attorneys’ fees, and other remedies. Zymergen intends to defend vigorously against such allegations. On November 9, 2021, one of Zymergen’s then purported shareholders filed a putative derivative lawsuit in the United States District Court for the Northern District of California that is captioned Mellor v. Hoffman, et al., Case No. 3:21-cv-08723-VC. The complaint names certain of Zymergen’s former officers and directors as defendants and Zymergen as nominal defendant based on allegations substantially similar to those in the securities class action. The complaint purports to assert claims on Zymergen’s behalf for breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, corporate waste, and contribution under the federal securities laws and seeks corporate reforms, unspecified damages and restitution, and fees and costs. Zymergen intends to defend vigorously against such allegations. On or about February 7, 2023, a complaint was filed by Fortis Advisors LLC, solely in its capacity as Stockholders’ Representative for the holders of convertible promissory notes of Lodo Therapeutics Corporation (“Lodo”), against the Company's subsidiary, Zymergen, in Delaware Superior Court. The complaint purports to allege violations of California securities laws based on Zymergen’s exchange of its common stock for convertible promissory notes issued by Lodo in connection with Zymergen’s May 2021 acquisition of Lodo. The complaint seeks damages in an unspecified amount, attorneys’ fees, and other remedies. Zymergen intends to defend vigorously against such allegations. In addition, certain government agencies, including the SEC, have requested information related to Zymergen’s August 3, 2021 disclosure. Zymergen is cooperating fully.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	9. Stock-Based Compensation The following table summarizes stock-based compensation expense by financial statement line item in the Company’s condensed consolidated statement of operations and comprehensive loss for the periods presented (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Research and development $ 39,927 $ 216,838 $ 86,427 $ 477,846 General and administrative 21,561 389,677 48,047 781,490 Total $ 61,488 $ 606,515 $ 134,474 $ 1,259,336 The Company grants stock-based incentive awards pursuant to the 2021 Incentive Award Plan (the “2021 Plan”) and the 2022 Inducement Plan (the “2022 Inducement Plan”). As of June 30, 2023 , there were approximately 187.9 million shares and 8.3 million shares available for future issuance under the 2021 Plan and 2022 Inducement Plan, respectively. Stock Options A summary of stock option activity for the six months ended June 30, 2023 is presented below: Number (1) Weighted Weighted Aggregate (2) (in thousands) (in years) (in thousands) Outstanding as of December 31, 2022 10,501 $ 0.34 Granted 979 1.90 Exercised ( 1,572 ) 0.01 Outstanding as of June 30, 2023 9,908 0.55 2.55 $ 14,614 Exercisable as of June 30, 2023 8,707 0.30 1.56 14,614 (1) Excludes 1.9 million shares underlying options issued outside the accounting for compensation awards under ASC 718. (2) The aggregate intrinsic value is calculated as the difference between the Company's closing stock price on the last trading day of the quarter and the exercise prices, multiplied by the number of in-the-money stock options. The aggregate intrinsic value of stock options exercised during the six months ended June 30, 2023 and 2022 was $ 2.9 million and $ 9.1 million, respectively. During the six months ended June 30, 2023 and 2022, the Company granted options with an aggregate fair value of $ 1.4 million and $ 1.2 million, respectively. The weighted-average fair value of options granted during the six months ended June 30, 2023 and 2022 was $ 1.43 and $ 1.84 per share, respectively, and was calculated using the following key input assumptions in the Black-Scholes option-pricing model: Six Months Ended June 30, 2023 2022 Risk-free interest rate 3.94 % 3.25 % Expected volatility 93 % 75 % Expected term (in years) 5.5 5.5 Dividend yield 0 % 0 % As of June 30, 2023 , there was $ 1.8 million of unrecognized compensation expense related to stock options to be recognized over a weighted-average period of 1.2 years. Restricted Stock and Restricted Stock Units During the six months ended June 30, 2022 , the Company cash settled approximately 3.2 million restricted stock units (“RSUs”) granted to non-employee directors for a total cash payment of $ 9.8 million. A summary of the RSU and restricted stock award (“RSA”) activity for the six months ended June 30, 2023 is presented below: Restricted Stock Units Restricted Stock Awards Number of Weighted Number of Weighted Nonvested as of December 31, 2022 134,436 $ 5.84 4 $ 1.99 Granted 88,869 1.32 — — Vested ( 27,217 ) 6.83 ( 4 ) 1.99 Forfeited ( 11,852 ) 4.24 — — Nonvested as of June 30, 2023 184,236 3.61 — — The weighted average grant date fair value of RSUs granted during the six months ended June 30, 2023 and 2022 was $ 1.32 and $ 3.79 , respectively. No RSAs were granted during the six months ended June 30, 2023 and 2022. The aggregate grant date fair value of the RSUs that vested during the six months ended June 30, 2023 and 2022 was $ 185.9 million and $ 199.3 million, respectively. The aggregate grant date fair value of the RSAs that vested during the six months ended June 30, 2023 and 2022 was de minimis. As of June 30, 2023 , there was $ 413.6 million of unrecognized compensation expense related to RSUs to be recognized over a weighted-average period of 3.2 years. Earnouts Earnout shares represent equity awards in the form of RSUs and RSAs that were granted to existing shareholders of the Company as of the closing date of the Company's merger with SRNG on September 16, 2021 (the “Closing Date”). The earnout shares are subject to the same terms and conditions as the underlying awards (including with respect to vesting and termination-related provisions). Additionally, t he earnout shares are subject to a market condition that will be met when the trading price of the Company's common stock is greater than or equal to $ 12.50 , $ 15.00 , $ 17.50 and $ 20.00 for any 20 trading days within any period of 30 consecutive trading days, on or before the fifth anniversary of the Closing Date (collectively, the “Earnout Targets”). The first Earnout Target of $ 12.50 per share was met on November 15, 2021. A summary of activity during the six months ended June 30, 2023 for the earnout shares is presented below: Number of Weighted Nonvested as of December 31, 2022 23,520 $ 12.79 Vested ( 307 ) 13.34 Forfeited ( 241 ) 12.25 Nonvested as of June 30, 2023 22,972 12.79 The aggregate grant date fair value of the earnout shares that vested during the six months ended June 30, 2023 and 2022 was $ 4.1 million and $ 5.8 million, respectively. As of June 30, 2023 , there was $ 9.9 million of unrecognized compensation expense related to earnout shares to be recognized over a weighted-average period of 1.7 years.

Revenue Recognition

Revenue Recognition	6 Months Ended
	Jun. 30, 2023
Revenue from Contract with Customer [Abstract]
Revenue Recognition	10. Revenue Recognition Disaggregation of Revenue The following table sets forth the percentage of Cell Engineering revenues by industry based on total Cell Engineering revenue: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Pharma and biotech 40 % 15 % 35 % 16 % Agriculture 20 % 4 % 23 % 4 % Consumer and technology 14 % 61 % 12 % 52 % Food and nutrition 11 % 9 % 13 % 9 % Industrial and environment 11 % 8 % 12 % 16 % Government and defense 4 % 3 % 5 % 3 % Total Cell Engineering revenue 100 % 100 % 100 % 100 % For the three months ended June 30, 2023 and 2022, the Company’s revenue from customers within the United States comprised 84 % and 82 %, respectively, of total revenue. For the six months ended June 30, 2023 and 2022, the Company’s revenue from customers within the United States comprised 84 % and 91 %, respectively, of total revenue. Contract Balances The Company recognizes a contract asset when the Company transfers goods or services to a customer before the customer pays consideration or before payment is due, excluding any amounts presented as accounts receivable. The Company had no contract asset balances as of June 30, 2023 and December 31, 2022. Contract liabilities, or deferred revenue, primarily consist of payments received in advance of performance under the contract or when the Company has an unconditional right to consideration under the terms of the contract before it transfers goods or services to the customer. The Company’s collaborative arrangements with its investees and related parties typically include upfront payments consisting of cash or non-cash consideration for future research and development services and non-cash consideration in the form of convertible financial instruments and equity securities for licenses that will be transferred in the future. The Company records the upfront cash payments and fair value of the convertible financial instruments and equity securities as deferred revenue. The Company also invoices customers based on contractual billing schedules, which results in the recording of deferred revenue to the extent payment is received prior to the Company’s performance of the related services. Contract liabilities are recognized as revenue as (or when) the Company performs under the contract. During the six months ended June 30, 2023, the Company recogniz ed $ 44.1 million of revenue that was included in the contract liabilities balance of $ 222.6 million as of December 31, 2022. During the six months ended June 30, 2022 , the Company recognized $ 25.2 million of revenue that was included in the contract liabilities balance of $ 189.2 million as of December 31, 2021. Performance Obligations The aggregate amount of the transaction price that was allocated to performance obligations that have not yet been satisfied or are partially satisfied as of June 30, 2023 and December 31, 2022 was $ 115.1 million and $ 123.5 million, respectively. The Company has elected the practical expedient not to provide the remaining performance obligation disclosures related to contracts for which the Company recognizes revenue on a cost-plus basis in the amount to which it has the right to invoice, and for contracts with a term of one year or less. As of June 30, 2023 , of the performance obligations not yet satisfied or partially satisfied, nearly all is expected to be recognized as revenue during the years 2023 t o 2027 .

Segment Information

Segment Information	6 Months Ended
	Jun. 30, 2023
Segment Reporting [Abstract]
Segment Information	11. Segment Information The Company has identified two operating and reportable segments: Cell Engineering and Biosecurity. The following table presents summary results of the Company’s reportable segments for the periods indicated (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2023 2022 (as adjusted)* 2023 2022 (as adjusted)* Revenue: Cell Engineering $ 45,283 $ 44,242 $ 79,379 $ 65,730 Biosecurity 35,285 100,376 81,891 247,293 Total revenue 80,568 144,618 161,270 313,023 Segment cost of revenue: Biosecurity 18,096 63,911 40,471 149,343 Segment research and development expense: Cell Engineering 86,083 63,948 184,605 112,359 Biosecurity 528 443 1,095 960 Total segment research and development expense 86,611 64,391 185,700 113,319 Segment general and administrative expense: Cell Engineering 50,907 36,601 112,599 63,294 Biosecurity 16,699 12,409 30,655 25,644 Total segment general and administrative expense 67,606 49,010 143,254 88,938 Segment operating (loss) income: Cell Engineering ( 91,707 ) ( 56,307 ) ( 217,825 ) ( 109,923 ) Biosecurity ( 38 ) 23,613 9,670 71,346 Total segment operating loss ( 91,745 ) ( 32,694 ) ( 208,155 ) ( 38,577 ) Operating expenses not allocated to segments: Stock-based compensation (1) 62,477 607,270 137,677 1,266,305 Depreciation and amortization 17,652 9,028 36,610 17,968 Asset impairment 9,001 — 9,001 — Change in fair value of contingent consideration liability 3,276 ( 1,213 ) 8,453 300 Loss from operations $ ( 184,151 ) $ ( 647,779 ) $ ( 399,896 ) $ ( 1,323,150 ) * As adjusted to reflect the impact of the adoption of ASC 842 as of January 1, 2022. See Note 1 for a summary of the adjustments. (1) Includes $ 1.0 million and $ 0.8 million in employer payroll taxes for the three months ended June 30, 2023 and 2022 , respectively, and $ 3.2 million and $ 7.0 million in employer payroll taxes for the six months ended June 30, 2023 and 2022, respectively.

Significant Collaboration Trans

Significant Collaboration Transactions	6 Months Ended
	Jun. 30, 2023
Significant Collaboration Transactions [Abstract]
Significant Collaboration Transactions	12. Significant Collaboration Transactions BiomEdit, LLC In April 2022, the Company, along with one of its investors and third-party investors, including Elanco Animal Health Inc. (“Elanco”), launched BiomEdit, LLC (“BiomEdit”), a microbiome innovation company that intends to discover, design and develop novel probiotics, microbiome derived bioactives and engineered microbial medicines in the field of animal health. Concurrently with the launch, the Company entered into (i) an Intellectual Property Contribution Agreement (“BiomEdit IP Agreement”) that granted BiomEdit a license to certain of the Company’s intellectual property, (ii) a Technical Development Agreement (“BiomEdit TDA”) that establishes the terms under which the Company will provide technical research and development services, and (iii) a Common Unit Issuance Agreement (“BiomEdit CUIA”) which compensates the Company for its intellectual property contribution. Contemporaneous with these agreements, BiomEdit entered into a Series A Preferred Unit Purchase Agreement under which it sold 6.7 million Series A preferred units to one of the Company’s investors and a third-party investor, for aggregate proceeds of approximately $ 32.5 million. After the initial closing, BiomEdit may issue up to an additional 1.5 million Series A preferred units (the “Additional Units”) to one or more purchasers reasonably acceptable to the existing holders of Series A preferred units. In a subsequent closing during the first quarter of 2023, BiomEdit sold 0.8 million Additional Units for aggregate proceeds of $ 4.0 million and closed its Series A preferred unit financing. Under the BiomEdit IP Agreement, the Company licensed certain intellectual property to BiomEdit for use in the development or production of BiomEdit’s products that the parties will subsequently agree to research and develop under technical development plans (“TDP”). The license rights provide BiomEdit with the ability to commercialize the specified products from the corresponding TDP under the BiomEdit TDA. In return for the license to the intellectual property, BiomEdit issued the Company 3.9 million common units upon execution of the BiomEdit CUIA, with 0.7 million of those units subject to forfeiture in the event BiomEdit does not sell all of the Additional Units. Under the BiomEdit TDA, the parties jointly agree on TDPs, through equal representation on a joint steering committee, under which the Company will perform agreed-upon research and development services in return for consideration on a fixed fee or cost-plus basis for all services provided. Accounting Analysis The common unit investment in BiomEdit is considered an equity method investment as a result of the Company’s ability to exercise significant influence over BiomEdit’s financial and operating policies through its ownership of common units. The initial carrying value of the equity method investment in BiomEdit is the fair value of the nonforfeitable common units of $ 8.9 million received in exchange for the BiomEdit IP Agreement which, as discussed below, is being accounted for as non-cash consideration under ASC 606. The Company determined that the 0.7 million common units held by Ginkgo subject to forfeiture are considered variable consideration that is fully constrained at contract inception until the contingencies related to the issuance of the additional shares are resolved. Upon the closing of BiomEdit's Series A preferred unit financing in the first quarter of 2023, Ginkgo forfeited 0.3 million common units and retained 0.4 million common units for total consideration of $ 1.1 million. The fair value of BiomEdit’s common units was determined at inception of the agreements using the option pricing method. The option pricing method used a back-solve methodology to infer the total equity value based on the pricing of the Series A preferred unit financing, which was contemporaneous with the BiomEdit IP Agreement. The Series A preferred units issued by BiomEdit receive a liquidation preference prior to common units. As such, the Company concluded that this represents a substantive profit-sharing arrangement, and the Company is recognizing earnings and losses on the equity method investment using the HLBV method. The Company recorded a $ 1.5 million loss on its equity method investment in BiomEdit during the six months ended June 30, 2023, which reduced the carrying value of the equity method investment in BiomEdit to zero. There is no commitment for the Company to provide further financial support to BiomEdit, and therefore the carrying value of the equity method investment will not be reduced below zero. The relationship with BiomEdit is a vendor-customer relationship and is within the scope of ASC 606, as the provision of services and corresponding license rights are considered a part of the Company’s ordinary activities. The common units issued to the Company represent non-cash consideration. While the BiomEdit TDA has been executed by the parties and provides the payment terms for future services, the BiomEdit TDA does not provide for any transfer of goods or services between the parties. However, the Company will provide licenses and services upon execution of the contemplated TDPs. Accordingly, the Company concluded that the BiomEdit TDA, in combination with the BiomEdit CUIA, met the definition of a contract under ASC 606. Each TDP executed under the BiomEdit TDA will be accounted for in accordance with ASC 606. The Company’s performance obligations under the BiomEdit TDA consist of four material rights to future technical research and development services and commercial licenses under individual TDPs that the Company expects to execute. The material rights represent an advance payment for the license rights, which will be granted upon the execution of future TDPs. As there is no additional payment for these license rights when future TDPs are executed, the Company has determined that there is a material right associated with each of the contemplated TDPs under the BiomEdit TDA. The Company has allocated approximately $ 2.2 million of the upfront non-cash consideration to each of the four material rights based on the estimated standalone selling price of the performance obligations. During the first quarter of 2023, the additional $ 1.1 million of non-cash consideration, which represents previously constrained variable consideration, was allocated to each of the four performance obligations under the arrangement with BiomEdit of $ 0.3 million each consistent with the initial relative selling price allocation. Upon the execution of a TDP underlying a material right, the Company is obligated to provide technical research and development services under the TDP and a license to applicable patents and other intellectual property designed and developed under the TDP. The technical research and development services and license provided under a TDP are highly interdependent and interrelated with one another. Without the Company’s knowledge, expertise, and platform, there would not be a licensable strain or other commercializable product to transfer to BiomEdit. Further, BiomEdit has rights to intellectual property created as part of each TDP, irrespective of the result of the development. Therefore, each executed TDP underlying a material right consists of one combined performance obligation for the technical research and development services and license to be provided by the Company. For each TDP underlying a material right, the transaction price consists of (i) either a fixed fee or, if a cost-plus arrangement, variable consideration for the most likely amount of estimated consideration to be received and (ii) non-cash consideration allocated to the material rights. As the services performed by the Company under a TDP create or enhance an asset that BiomEdit controls as the asset is created or enhanced, the Company satisfies the performance obligation and recognizes revenue over time. The Company uses an input method that compares total costs incurred relative to total estimated cost to complete to estimate progress under the contract. Any revisions to the estimated total budgeted costs to complete, and the resulting impact on revenue recognition, are reflected in the period of the change through a cumulative catch-up adjustment. As of June 30, 2023 and December 31, 2022 the Company had a deferred revenue balance of $ 7.9 million and $ 8.1 million, respectively, with BiomEdit. During the three and six months ended June 30, 2023, the Company recognized revenue of $ 0.9 million and $ 1.8 million, respectively, from services provided to BiomEdit.

Net Loss per Share

Net Loss per Share	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Net Loss per Share	13. Net Loss per Share The Company computes net loss per share of Class A common stock and Class B common stock using the two-class method required for participating securities. The earnings per share amounts are the same for the different classes of common stock because the holders of each class are legally entitled to equal per share distributions whether through dividends or liquidation. The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to Ginkgo Bioworks Holdings, Inc. common stockholders for the periods presented because including them would have been anti-dilutive (in thousands): As of June 30, 2023 2022 Warrants to purchase Class A common stock 51,825 51,825 Outstanding stock options 11,796 21,453 Unvested RSUs 184,236 214,272 Unvested RSAs — 93 Earnout shares (1) 152,318 160,521 400,175 448,164 (1) Represents earnout shares for which the service-based vesting conditions and/or market conditions have not been met.

Related Parties

Related Parties - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Related Party Transactions [Abstract]
Related Parties	14. Related Parties The Company’s significant transactions with its related parties are primarily comprised of revenue generating activities under collaboration and license agreements. Significant related party transactions included in the condensed consolidated balance sheet are summarized below (in thousands): As of June 30, As of December 31, 2023 2022 Accounts receivable: Allonnia, LLC $ 228 $ 140 Arcaea, LLC 68 335 Verb Biotics, LLC 285 361 Ayana Bio, LLC 202 403 BiomEdit, LLC 116 288 Other equity investees — 31 $ 899 $ 1,558 Deferred revenue, current and non-current: Motif FoodWorks, Inc. $ 51,996 $ 52,018 Genomatica, Inc. 4,262 6,250 Allonnia, LLC 35,853 35,876 Arcaea, LLC 33,226 38,334 BiomEdit, LLC 7,947 8,144 Other equity investees 495 875 $ 133,779 $ 141,497 Significant related party transactions included in the condensed consolidated statement of operations and comprehensive loss are summarized below (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Cell Engineering revenue: Joyn Bio, LLC $ — $ 947 $ — $ 2,129 Motif FoodWorks, Inc. 2 507 3 1,852 Genomatica, Inc. 779 2,405 1,988 5,763 Allonnia, LLC 159 439 245 3,660 Arcaea, LLC 4,234 2,363 5,696 6,287 Verb Biotics, LLC 81 639 518 938 Ayana Bio, LLC 184 — 636 — BiomEdit, LLC 869 — 1,777 — Other equity investees 199 673 349 872 $ 6,507 $ 7,973 $ 11,212 $ 21,501 Refer to Note 4 for additional details on the Company’s investments and equity method investments held in its related parties.
Accounts receivable - related parties	$ 899	$ 1,558

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in conformity with the rules and regulations of the Securities and Exchange Commission and generally accepted accounting principles in the United States (“GAAP”) for interim financial reporting. Accordingly, certain detailed disclosures which would normally be included with annual financial statements have been omitted. In the opinion of management, all normal recurring adjustments necessary for a fair presentation have been made. These condensed consolidated financial statements should be read in conjunction with the Company's 2022 Annual Report on Form 10-K. Interim results are not necessarily indicative of results for a full year.
Principles of Consolidation	Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries, majority owned subsidiaries and variable interest entities if the Company is the primary beneficiary. All intercompany accounts and transactions have been eliminated.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and the disclosure of contingent liabilities in the condensed consolidated financial statements. Estimates used in the preparation of these condensed consolidated financial statements include, among others, revenue recognition, stock-based compensation, the fair value of assets acquired and liabilities assumed in a business combination, the fair value of non-cash consideration received from customers, the fair value of certain notes receivable, the fair value of certain investments including equity method investments, the fair value of warrant liabilities, the allocation of equity method investment losses under the hypothetical liquidation at book value (“HLBV”) method, the incremental borrowing rate used in determining lease liabilities, allowance for credit losses, accrued expenses and income taxes. The Company bases its estimates on historical experience and other market-specific or relevant assumptions that it believes to be reasonable under the circumstances. Reported amounts and disclosures reflect the overall economic conditions that management believes are most likely to occur, and the anticipated measures management intends to take. Actual results could differ materially from those estimates. All revisions to accounting estimates are recognized in the period in which the estimates are revised.
Significant Accounting Policies	Significant Accounting Policies There have been no new or material changes to the Company’s significant accounting policies during the six months ended June 30, 2023 as compared to the significant accounting policies described in Note 2 to the Company's 2022 consolidated financial statements included in the 2022 Annual Report on Form 10-K.
Retrospective Application of a Change in Accounting Principle	Retrospective Application of a Change in Accounting Principle The Company adopted Accounting Standards Update No. 2016-02, Leases (“ASC 842”), which supersedes the guidance in Accounting Standards Codification Topic 840, Leases (“ASC 840”), effective January 1, 2022. As the Company elected the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the Jumpstart Our Business Startups Act of 2012, ASC 842 was adopted in connection with the preparation of the Company’s annual consolidated financial statements as of and for the year ended December 31, 2022. As such, the comparative information for the three and six months ended June 30, 2022 has been adjusted herein to reflect the impact of the adoption of ASC 842 as of January 1, 2022. Select line items from the condensed consolidated statement of operations and comprehensive loss reflecting the adoption of ASC 842 are as follows (in thousands): Three Months Ended June 30, 2022 Six Months Ended June 30, 2022 As Previously Reported Adjustments As Adjusted As Previously Reported Adjustments As Adjusted Costs and operating expenses: Research and development $ 289,188 $ 871 $ 290,059 $ 611,908 $ 1,727 $ 613,635 Total operating expenses 791,526 871 792,397 1,634,446 1,727 1,636,173 Loss from operations ( 646,908 ) ( 871 ) ( 647,779 ) ( 1,321,423 ) ( 1,727 ) ( 1,323,150 ) Other income (expense): Interest income, net 1,674 590 2,264 1,277 1,164 2,441 Other income (expense), net ( 51 ) 281 230 1,586 563 2,149 Total other income (expense), net ( 23,707 ) 871 ( 22,836 ) 58,031 1,727 59,758 Select line items from the condensed consolidated statements of stockholders’ equity reflecting the adoption of ASC 842 are as follows (in thousands): As of June 30, 2022 As Previously Reported Adjustments As Adjusted Accumulated deficit $ ( 3,557,255 ) $ 5,195 $ ( 3,552,060 ) Total stockholders' equity 1,567,056 5,195 1,572,251 Select line items from the condensed consolidated statements of cash flows reflecting the adoption of ASC 842 are as follows (in thousands): Six Months Ended June 30, 2022 As Previously Reported Adjustments As Adjusted Cash flows from operating activities: Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization $ 19,096 $ ( 1,128 ) $ 17,968 Amortization of finance lease right-of-use assets — 1,004 1,004 Non-cash lease expense — 7,536 7,536 Changes in operating assets and liabilities: Prepaid expenses and other current assets 4,973 ( 600 ) 4,373 Accrued expenses and other current liabilities ( 12,758 ) ( 123 ) ( 12,881 ) Operating lease liabilities, current and non-current — ( 5,332 ) ( 5,332 ) Deferred rent, non-current 1,468 ( 1,468 ) — Cash flows from financing activities: Principal payments on finance leases — ( 609 ) ( 609 ) Principal payments on capital leases and lease financing obligation ( 720 ) 720 —
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements There were no new recently issued accounting pronouncements that are of significance or potential significance to the Company from those disclosed herein and within Note 2 to the Company's 2022 consolidated financial statements included in the 2022 Annual Report on Form 10-K.

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Summary of Condensed Consolidated Statements of Operations and Comprehensive Loss	Select line items from the condensed consolidated statement of operations and comprehensive loss reflecting the adoption of ASC 842 are as follows (in thousands): Three Months Ended June 30, 2022 Six Months Ended June 30, 2022 As Previously Reported Adjustments As Adjusted As Previously Reported Adjustments As Adjusted Costs and operating expenses: Research and development $ 289,188 $ 871 $ 290,059 $ 611,908 $ 1,727 $ 613,635 Total operating expenses 791,526 871 792,397 1,634,446 1,727 1,636,173 Loss from operations ( 646,908 ) ( 871 ) ( 647,779 ) ( 1,321,423 ) ( 1,727 ) ( 1,323,150 ) Other income (expense): Interest income, net 1,674 590 2,264 1,277 1,164 2,441 Other income (expense), net ( 51 ) 281 230 1,586 563 2,149 Total other income (expense), net ( 23,707 ) 871 ( 22,836 ) 58,031 1,727 59,758
Summary of condensed consolidated statements of stockholders' equity reflecting the adoption of ASC 842	Select line items from the condensed consolidated statements of stockholders’ equity reflecting the adoption of ASC 842 are as follows (in thousands): As of June 30, 2022 As Previously Reported Adjustments As Adjusted Accumulated deficit $ ( 3,557,255 ) $ 5,195 $ ( 3,552,060 ) Total stockholders' equity 1,567,056 5,195 1,572,251
Summary of condensed consolidated statements of cash flows reflecting the adoption of ASC 842	Select line items from the condensed consolidated statements of cash flows reflecting the adoption of ASC 842 are as follows (in thousands): Six Months Ended June 30, 2022 As Previously Reported Adjustments As Adjusted Cash flows from operating activities: Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization $ 19,096 $ ( 1,128 ) $ 17,968 Amortization of finance lease right-of-use assets — 1,004 1,004 Non-cash lease expense — 7,536 7,536 Changes in operating assets and liabilities: Prepaid expenses and other current assets 4,973 ( 600 ) 4,373 Accrued expenses and other current liabilities ( 12,758 ) ( 123 ) ( 12,881 ) Operating lease liabilities, current and non-current — ( 5,332 ) ( 5,332 ) Deferred rent, non-current 1,468 ( 1,468 ) — Cash flows from financing activities: Principal payments on finance leases — ( 609 ) ( 609 ) Principal payments on capital leases and lease financing obligation ( 720 ) 720 —

Business Combination (Tables)

Business Combination (Tables) - FGen [Member]	6 Months Ended
	Jun. 30, 2023
Business Acquisition [Line Items]
Summary of Acquisition Date Fair Value of the Consideration Transferred	The consideration paid was comprised of common stock and contingent consideration as follows (in thousands): Fair value of Class A common stock $ 17,015 Fair value of contingent consideration - restricted stock 3,842 Fair value of contingent consideration - milestones 8,464 Total FGen consideration $ 29,321
Fair Values of Assets Acquired and Liabilities Assumed	The following table presents the final allocation of the purchase price to the assets acquired and liabilities assumed as of the acquisition date (in thousands): Preliminary Allocation Measurement Period Adjustment (3) Final Allocation Cash and cash equivalents $ 1,430 $ $ 1,430 Accounts receivable 144 — 144 Other non-current assets 10 — 10 Property and equipment 146 ( 112 ) 34 Intangible assets (1) 21,100 — 21,100 Goodwill (2) 11,001 ( 386 ) 10,615 Accounts payable and accrued expenses ( 29 ) — ( 29 ) Deferred revenue ( 104 ) — ( 104 ) Deferred tax liability ( 4,377 ) 498 ( 3,879 ) Net assets acquired $ 29,321 $ — $ 29,321 (1) Estimated useful life of 15 years . (2) Non-deductible for tax purposes. (3) Represents adjustments related to tangible assets acquired and estimated tax liabilities with a corresponding net decrease to goodwill.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2023
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Summary of Assets and Liabilities That Are Measured At Fair Value On Recurring Basis	The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis (in thousands): As of June 30, 2023 Classification Total Level 1 Level 2 Level 3 Assets: Money market funds Cash and cash equivalents $ 1,066,056 $ 1,066,056 $ — $ — Synlogic, Inc. warrants (1) Investments 1,095 — 1,095 — Marketable equity securities Investments 19,876 19,876 — — Loan receivable Prepaid expenses and other current assets 358 — — 358 Notes receivable Other non-current assets 38,950 — 30,000 8,950 Total assets $ 1,126,335 $ 1,085,932 $ 31,095 $ 9,308 Liabilities: Public Warrants Warrant liabilities $ 8,970 $ 8,970 $ — $ — Private Placement Warrants (3) Warrant liabilities 5,176 — 141 5,035 Contingent consideration Accrued expenses and other current liabilities 22,945 — — 22,945 Contingent consideration Other non-current liabilities 7,617 — — 7,617 Total liabilities $ 44,708 $ 8,970 $ 141 $ 35,597 As of December 31, 2022 Classification Total Level 1 Level 2 Level 3 Assets: Money market funds Cash and cash equivalents $ 1,089,026 $ 1,089,026 $ — $ — Synlogic, Inc. warrants (1) Investments 1,937 — 1,937 — Marketable equity securities (2) Investments 25,714 21,312 4,402 — Notes receivable Other non-current assets 37,660 — 30,000 7,660 Total assets $ 1,154,337 $ 1,110,338 $ 36,339 $ 7,660 Liabilities: Public Warrants Warrant liabilities $ 6,900 $ 6,900 $ — $ — Private Placement Warrants (3) Warrant liabilities 3,968 — 108 3,860 Contingent consideration Accrued expenses and other current liabilities 6,378 — — 6,378 Contingent consideration Other non-current liabilities 18,095 — — 18,095 Total liabilities $ 35,341 $ 6,900 $ 108 $ 28,333 (1) The fair value of Synlogic, Inc. warrants is calculated as the quoted price of the underlying common stock, less the unpaid exercise price of the warrants. (2) Marketable equity securities classified as Level 2 reflect a discount for lack of marketability due to regulatory sales restrictions. (3) The fair value of Private Placement Warrants classified as Level 2 is equivalent to that of Public Warrants as the transfer of Private Placement Warrants to anyone other than the initial purchasers or any of their permitted transferees results in the Private Placement Warrants having substantially the same terms as the Public Warrants.
Schedule of Change in the Fair Value of the Warrant Liability	The following table provides a reconciliation of notes and loans receivable measured at fair value using Level 3 significant unobservable inputs for the six months ended June 30 (in thousands): 2023 2022 Balance at January 1, $ 7,660 $ 11,559 Additions 3,137 — Change in fair value ( 1,489 ) ( 292 ) Balance at June 30, $ 9,308 $ 11,267
Summary of Fair Value Measurements Inputs	The following table provides quantitative information regarding Level 3 inputs used in the recurring valuation of the Private Placement Warrants as of their measurement dates: June 30, 2023 December 31, 2022 Exercise price $ 11.50 $ 11.50 Stock price $ 1.86 $ 1.69 Volatility 79.0 % 71.5 % Term (in years) 3.21 3.71 Risk-free interest rate 4.49 % 4.11 %
Summary of recurring Level 3 fair value measurements of contingent consideration liabilities	The following table provides quantitative information regarding Level 3 inputs used in the fair value measurements of contingent consideration liabilities as of the periods presented: June 30, 2023 December 31, 2022 Contingent Consideration Liability Valuation Technique Unobservable Input Range Range Earnout payments (FGen, Dutch DNA, Circularis and Altar acquisitions) Probability-weighted present value Probability of payment 1 % - 95 % 2 % - 100 % Discount rate 13.5 % - 14.6 % 12.2 % - 13.1 % Earnout payments (Dutch DNA acquisition) Discounted cash flow Projected years of payments 2025 - 2028 2025 - 2028 Discount rate 11.5 % 12.0 %
Contingent Consideration [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Schedule of Change in the Fair Value of the Warrant Liability	The following table provides a reconciliation of the contingent consideration measured at fair value using Level 3 significant unobservable inputs for the six months ended June 30 (in thousands): 2023 2022 Balance at January 1, $ 24,473 $ 8,467 Additions — 12,306 Change in fair value 8,453 300 Settlements and payments ( 2,364 ) ( 2,644 ) Balance at June 30, $ 30,562 $ 18,429
Private Placement Warrants [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Schedule of Change in the Fair Value of the Warrant Liability	The following table provides a reconciliation of the Private Placement Warrants measured at fair value using Level 3 significant unobservable inputs for the six months ended June 30 (in thousands): 2023 2022 Balance at January 1, $ 3,860 $ 58,558 Change in fair value 1,175 ( 49,549 ) Balance at June 30, $ 5,035 $ 9,009

Supplemental Financial Inform_2

Supplemental Financial Information (Tables)	6 Months Ended
	Jun. 30, 2023
Supplemental Financial Statement Information [Abstract]
Schedule of Cash, Cash Equivalents and Restricted Cash	The reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheet to the totals shown within the condensed consolidated statement of cash flows is as follows (in thousands): As of June 30, 2023 2022 Cash and cash equivalents $ 1,105,787 $ 1,377,152 Restricted cash included in prepaid expenses and other current assets (1) 22,483 4,239 Restricted cash included in other non-current assets (1) 43,791 39,444 Total cash, cash equivalents and restricted cash $ 1,172,061 $ 1,420,835 (1) I ncludes cash balances collateralizing letters of credit associated with the Company’s facility leases and a customer prepayment requiring segregation and restrictions in its use in accordance with the customer agreement.
Schedule of Inventory, Net	Inventory, net consisted of the following (in thousands): As of June 30, As of December 31, 2023 2022 Finished goods $ 4,435 $ 6,556 Raw materials 905 1,590 Less: inventory reserve ( 4,949 ) ( 3,782 ) Inventory, net $ 391 $ 4,364
Summary of Property and Equipment Net	Property, plant, and equipment, net consisted of the following (in thousands): As of June 30, As of December 31, 2023 2022 Lab equipment $ 180,025 $ 183,292 Leasehold improvements 136,197 125,307 Buildings and facilities 46,927 46,019 Construction in progress 19,831 23,426 Computer equipment and software 15,322 15,219 Furniture and fixtures 8,352 8,206 Land 6,060 6,060 Total property, plant, and equipment 412,714 407,529 Less: Accumulated depreciation and amortization ( 118,470 ) ( 92,756 ) Property, plant, and equipment, net $ 294,244 $ 314,773
Schedule of Capitalization	The following table presents the Company’s authorized, issued, and outstanding common stock as of the dates indicated (in thousands): Authorized Issued Outstanding Common stock as of June 30, 2023: Class A 10,500,000 1,595,167 1,478,611 Class B 4,500,000 378,273 356,093 Class C 800,000 120,000 120,000 15,800,000 2,093,440 1,954,704 Common stock as of December 31, 2022: Class A 10,500,000 1,448,234 1,337,499 Class B 4,500,000 383,649 354,477 Class C 800,000 200,000 200,000 15,800,000 2,031,883 1,891,976
Schedule of Supplemental Cash Flow Information	The following table presents non-cash investing and financing activities (in thousands): Six Months Ended June 30, 2023 2022 (as adjusted)* Supplemental disclosure of non-cash investing and financing activities: ROU Asset obtained in exchange for new operating lease liabilities upon adoption of ASC 842 $ — $ 147,744 ROU Asset obtained in exchange for new finance lease liabilities upon adoption of ASC 842 — 3,397 ROU Asset obtained in exchange for new operating lease liabilities 13,649 28,000 ROU Asset obtained in exchange for new finance lease liabilities — 1,096 Purchases of property and equipment included in accounts payable and accrued expenses 2,324 6,741 Equity received in related parties — 8,873 Convertible financial instruments received for Cell Engineering services 5,595 11,939 Equity securities and warrants received for Cell Engineering services 12,493 3,423 Settlement of contingent consideration - restricted stock 2,262 — Common stock issued for business and asset acquisitions 3,581 17,015 Contingent consideration for business acquisition — 12,306 * As adjusted to reflect the impact of the adoption of ASC 842 as of January 1, 2022. See Note 1 for a summary of the adjustments.

Investments and Equity Method_2

Investments and Equity Method Investments (Tables)	6 Months Ended
	Jun. 30, 2023
Equity Method Investments and Joint Ventures [Abstract]
Schedule of Investments and Equity Method Investments	Investments and equity method investments consisted of the following (in thousands): As of June 30, As of December 31, 2023 2022 Investments: Genomatica, Inc. preferred stock $ 44,885 $ 44,885 Synlogic, Inc. common stock 2,727 4,819 Synlogic, Inc. warrants 1,095 1,937 Marketable equity securities 17,149 20,895 Non-marketable equity securities 29,259 17,544 SAFEs 24,829 22,108 Total $ 119,944 $ 112,188 Equity method investments (1) : BiomEdit, LLC $ — $ 369 Other 1,120 1,174 Total $ 1,120 $ 1,543 (1) Equity method investments in Platform Ventures with a carrying value of zero as of June 30, 2023 and December 31, 2022 were excluded from the table. Losses on investments and equity method investments consisted of the following (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Loss on investments: Synlogic, Inc. common stock $ ( 1,281 ) $ ( 7,926 ) $ ( 2,092 ) $ ( 8,053 ) Synlogic, Inc. warrants ( 514 ) ( 3,185 ) ( 841 ) ( 3,236 ) Genomatica, Inc. — ( 10,115 ) — ( 10,115 ) Marketable equity securities ( 326 ) ( 17,447 ) ( 3,747 ) ( 16,819 ) SAFEs — — ( 1,811 ) — Total $ ( 2,121 ) $ ( 38,673 ) $ ( 8,491 ) $ ( 38,223 ) Loss on equity method investments: Joyn Bio, LLC $ — $ ( 5,424 ) $ — $ ( 10,411 ) Verb Biotics, LLC — — — ( 15,900 ) BiomEdit, LLC — ( 4,552 ) ( 1,462 ) ( 4,552 ) Other ( 67 ) ( 190 ) ( 54 ) ( 190 ) Total $ ( 67 ) $ ( 10,166 ) $ ( 1,516 ) $ ( 31,053 )

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets, net (Tables)	6 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	Changes in the carrying amount of goodwill consisted of the following (in thousands): Balance as of December 31, 2022 $ 60,210 Impact of foreign currency translation 592 Measurement period adjustments ( 1,973 ) Balance as of June 30, 2023 $ 58,829 During the six months ended June 30, 2023 , the Company recognized a measurement period adjustment related to the Zymergen acquisition, which resulted in a decrease to goodwill of $ 2.2 million, an increase to accounts receivable of $ 1.8 million, and a decrease to accrued expenses and other current liabilities of $ 0.4 million. The adjustment was a result of updated information about facts and circumstances that existed at the acquisition date regarding the collectability of an acquired accounts receivable and accrued expenses under a collaboration agreement. Additionally, $ 0.2 million was added to goodwill related to the Altar SAS acquisition.
Schedule of Intangible Assets	Intangible assets, net consisted of the following (in thousands): Gross (1) Accumulated (1) Net Weighted Average June 30, 2023: Developed technology $ 118,134 $ ( 16,717 ) $ 101,417 9.0 Database 3,700 ( 371 ) 3,329 6.3 Customer relationships 380 ( 166 ) 214 1.1 Assembled workforce 190 ( 117 ) 73 0.5 Total intangible assets $ 122,404 $ ( 17,371 ) $ 105,033 December 31, 2022: Developed technology $ 115,824 $ ( 8,825 ) $ 106,999 9.4 Database 3,700 ( 107 ) 3,593 6.8 Customer relationships 380 ( 71 ) 309 1.6 Assembled workforce 190 ( 50 ) 140 1.0 Total intangible assets $ 120,094 $ ( 9,053 ) $ 111,041 (1) Gross carrying value and accumulated amortization include the impact of cumulative foreign currency translation adjustments.
Schedule of Estimated Future Amortization Expense	Amortization expense was $ 4.0 million and $ 0.8 million for the three months ended June 30, 2023 and 2022 , respectively, and $ 8.3 million and $ 1.3 million for the six months ended June 30, 2023 and 2022, respectively. As of June 30, 2023, estimated future amortization expense for identifiable intangible assets is as follows (in thousands): Remainder of 2023 $ 7,911 2024 15,630 2025 15,505 2026 15,505 2027 12,431 Thereafter 38,051 Total $ 105,033

Stock Based Compensation (Table

Stock Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Summary of Stock-based Compensation	The following table summarizes stock-based compensation expense by financial statement line item in the Company’s condensed consolidated statement of operations and comprehensive loss for the periods presented (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Research and development $ 39,927 $ 216,838 $ 86,427 $ 477,846 General and administrative 21,561 389,677 48,047 781,490 Total $ 61,488 $ 606,515 $ 134,474 $ 1,259,336
Summary of Stock Option Activity	A summary of stock option activity for the six months ended June 30, 2023 is presented below: Number (1) Weighted Weighted Aggregate (2) (in thousands) (in years) (in thousands) Outstanding as of December 31, 2022 10,501 $ 0.34 Granted 979 1.90 Exercised ( 1,572 ) 0.01 Outstanding as of June 30, 2023 9,908 0.55 2.55 $ 14,614 Exercisable as of June 30, 2023 8,707 0.30 1.56 14,614 (1) Excludes 1.9 million shares underlying options issued outside the accounting for compensation awards under ASC 718. (2) The aggregate intrinsic value is calculated as the difference between the Company's closing stock price on the last trading day of the quarter and the exercise prices, multiplied by the number of in-the-money stock options.
Summary of key input assumptions in the Black-Scholes option-pricing	the following key input assumptions in the Black-Scholes option-pricing model: Six Months Ended June 30, 2023 2022 Risk-free interest rate 3.94 % 3.25 % Expected volatility 93 % 75 % Expected term (in years) 5.5 5.5 Dividend yield 0 % 0 %
Summary of RSU and RSA Activity	A summary of the RSU and restricted stock award (“RSA”) activity for the six months ended June 30, 2023 is presented below: Restricted Stock Units Restricted Stock Awards Number of Weighted Number of Weighted Nonvested as of December 31, 2022 134,436 $ 5.84 4 $ 1.99 Granted 88,869 1.32 — — Vested ( 27,217 ) 6.83 ( 4 ) 1.99 Forfeited ( 11,852 ) 4.24 — — Nonvested as of June 30, 2023 184,236 3.61 — —
Summary of Activity For Earnout RSA	A summary of activity during the six months ended June 30, 2023 for the earnout shares is presented below: Number of Weighted Nonvested as of December 31, 2022 23,520 $ 12.79 Vested ( 307 ) 13.34 Forfeited ( 241 ) 12.25 Nonvested as of June 30, 2023 22,972 12.79

Revenue Recognition (Tables)

Revenue Recognition (Tables)	6 Months Ended
	Jun. 30, 2023
Disaggregation of Revenue [Abstract]
Disaggregation Of Revenue	The following table sets forth the percentage of Cell Engineering revenues by industry based on total Cell Engineering revenue: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Pharma and biotech 40 % 15 % 35 % 16 % Agriculture 20 % 4 % 23 % 4 % Consumer and technology 14 % 61 % 12 % 52 % Food and nutrition 11 % 9 % 13 % 9 % Industrial and environment 11 % 8 % 12 % 16 % Government and defense 4 % 3 % 5 % 3 % Total Cell Engineering revenue 100 % 100 % 100 % 100 %

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Jun. 30, 2023
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	The following table presents summary results of the Company’s reportable segments for the periods indicated (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2023 2022 (as adjusted)* 2023 2022 (as adjusted)* Revenue: Cell Engineering $ 45,283 $ 44,242 $ 79,379 $ 65,730 Biosecurity 35,285 100,376 81,891 247,293 Total revenue 80,568 144,618 161,270 313,023 Segment cost of revenue: Biosecurity 18,096 63,911 40,471 149,343 Segment research and development expense: Cell Engineering 86,083 63,948 184,605 112,359 Biosecurity 528 443 1,095 960 Total segment research and development expense 86,611 64,391 185,700 113,319 Segment general and administrative expense: Cell Engineering 50,907 36,601 112,599 63,294 Biosecurity 16,699 12,409 30,655 25,644 Total segment general and administrative expense 67,606 49,010 143,254 88,938 Segment operating (loss) income: Cell Engineering ( 91,707 ) ( 56,307 ) ( 217,825 ) ( 109,923 ) Biosecurity ( 38 ) 23,613 9,670 71,346 Total segment operating loss ( 91,745 ) ( 32,694 ) ( 208,155 ) ( 38,577 ) Operating expenses not allocated to segments: Stock-based compensation (1) 62,477 607,270 137,677 1,266,305 Depreciation and amortization 17,652 9,028 36,610 17,968 Asset impairment 9,001 — 9,001 — Change in fair value of contingent consideration liability 3,276 ( 1,213 ) 8,453 300 Loss from operations $ ( 184,151 ) $ ( 647,779 ) $ ( 399,896 ) $ ( 1,323,150 ) * As adjusted to reflect the impact of the adoption of ASC 842 as of January 1, 2022. See Note 1 for a summary of the adjustments. (1) Includes $ 1.0 million and $ 0.8 million in employer payroll taxes for the three months ended June 30, 2023 and 2022 , respectively, and $ 3.2 million and $ 7.0 million in employer payroll taxes for the six months ended June 30, 2023 and 2022, respectively.

Net Loss per Share (Tables)

Net Loss per Share (Tables)	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Summary Of Anti-Dilutive Shares	The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to Ginkgo Bioworks Holdings, Inc. common stockholders for the periods presented because including them would have been anti-dilutive (in thousands): As of June 30, 2023 2022 Warrants to purchase Class A common stock 51,825 51,825 Outstanding stock options 11,796 21,453 Unvested RSUs 184,236 214,272 Unvested RSAs — 93 Earnout shares (1) 152,318 160,521 400,175 448,164 (1) Represents earnout shares for which the service-based vesting conditions and/or market conditions have not been met.

Related Parties (Tables)

Related Parties (Tables)	6 Months Ended
	Jun. 30, 2023
Related Party Transactions [Abstract]
Summary of Condensed Consolidated Balance Sheets	Significant related party transactions included in the condensed consolidated balance sheet are summarized below (in thousands): As of June 30, As of December 31, 2023 2022 Accounts receivable: Allonnia, LLC $ 228 $ 140 Arcaea, LLC 68 335 Verb Biotics, LLC 285 361 Ayana Bio, LLC 202 403 BiomEdit, LLC 116 288 Other equity investees — 31 $ 899 $ 1,558 Deferred revenue, current and non-current: Motif FoodWorks, Inc. $ 51,996 $ 52,018 Genomatica, Inc. 4,262 6,250 Allonnia, LLC 35,853 35,876 Arcaea, LLC 33,226 38,334 BiomEdit, LLC 7,947 8,144 Other equity investees 495 875 $ 133,779 $ 141,497
Summary of Condensed Consolidated Statements of Operations and Comprehensive Loss	Significant related party transactions included in the condensed consolidated statement of operations and comprehensive loss are summarized below (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Cell Engineering revenue: Joyn Bio, LLC $ — $ 947 $ — $ 2,129 Motif FoodWorks, Inc. 2 507 3 1,852 Genomatica, Inc. 779 2,405 1,988 5,763 Allonnia, LLC 159 439 245 3,660 Arcaea, LLC 4,234 2,363 5,696 6,287 Verb Biotics, LLC 81 639 518 938 Ayana Bio, LLC 184 — 636 — BiomEdit, LLC 869 — 1,777 — Other equity investees 199 673 349 872 $ 6,507 $ 7,973 $ 11,212 $ 21,501

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Policies - Summary of condensed consolidated statement of operations and comprehensive loss reflecting the adoption of ASC 842 (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Costs and operating expenses:
Research and development	$ 144,282	$ 290,059	$ 306,921	$ 613,635	[1]
General and administrative	102,341	438,427	213,774	873,195	[1]
Total operating expenses	264,719	792,397	561,166	1,636,173	[1]
Loss from operations	(184,151)	(647,779)	(399,896)	(1,323,150)	[1]
Other income (expense):
Interest Income (Expense), Net	14,349	2,264	28,894	2,441	[1]
Other income (expense), net:	(3,224)	(230)	(6,152)	(2,149)	[1]
Total other income (expense), net	10,903	(22,836)	21,761	59,758	[1]
Loss before income taxes	(173,248)	(670,615)	(378,135)	(1,263,392)	[1]
Net Loss	(173,315)	(670,570)	(378,284)	(1,263,163)	[1]
Net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders	$ (173,315)	(668,825)	$ (378,284)	(1,259,330)	[1]
Adjustments [Member]
Costs and operating expenses:
Research and development		871		1,727
Total operating expenses		871		1,727
Loss from operations		(871)		(1,727)
Other income (expense):
Interest Income (Expense), Net		590		1,164
Other income (expense), net:		281		563
Total other income (expense), net		871		1,727
As Adjusted [Member]
Costs and operating expenses:
Research and development		290,059		613,635
Total operating expenses		792,397		1,636,173
Loss from operations		(647,779)		(1,323,150)
Other income (expense):
Interest Income (Expense), Net		2,264		2,441
Other income (expense), net:		230		2,149
Total other income (expense), net		(22,836)		59,758
As Previously Reported [Member]
Costs and operating expenses:
Research and development		289,188		611,908
Total operating expenses		791,526		1,634,446
Loss from operations		(646,908)		(1,321,423)
Other income (expense):
Interest Income (Expense), Net		1,674		1,277
Other income (expense), net:		(51)		1,586
Total other income (expense), net		$ (23,707)		$ 58,031
[1] As adjusted to reflect the impact of the adoption of Accounting Standards Codification Topic 842, Leases (“ASC 842”) as of January 1, 2022. See Note 1 for a summary of the adjustments.

Basis of Presentation and Sum_5

Basis of Presentation and Summary of Significant Accounting Policies - Summary of changes in condensed consolidated statements of stockholders equity reflecting the adoption of ASC 842 (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Accumulated deficit	$ (4,775,943)	$ (4,397,659)
As Previously Reported [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Accumulated deficit			$ (3,557,255)
Total stockholders' equity			1,567,056
As Adjusted [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Accumulated deficit			(3,552,060)
Total stockholders' equity			1,572,251
Adjustments [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Accumulated deficit			5,195
Total stockholders' equity			$ 5,195

Basis of Presentation and Sum_6

Basis of Presentation and Summary of Significant Accounting Policies - Summary of condensed consolidated statements of cash flows reflecting the adoption of ASC 842 (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities:
Net loss	$ (173,315)	$ (670,570)	$ (378,284)	$ (1,263,163)	[1]
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Depreciation and amortization			36,610	17,968
Amortization of finance lease right-of-use assets			569	1,004
Non-cash lease expense			16,327	7,536
Changes in operating assets and liabilities:
Prepaid expenses and other current assets			9,538	4,373
Accrued expenses and other current liabilities			(6,997)	(12,881)
Operating lease liabilities, current and non-current			(13,250)	(5,332)
Net cash used in operating activities			(164,118)	(119,306)
Cash flows from financing activities:
Principal payments on finance/capital leases and lease financing obligation			(648)	(609)
Net cash provided by financing activities			$ (2,269)	(2,035)
As Previously Reported [Member]
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Depreciation and amortization				19,096
Amortization of finance lease right-of-use assets				0
Non-cash lease expense				0
Changes in operating assets and liabilities:
Prepaid expenses and other current assets				4,973
Accrued expenses and other current liabilities				(12,758)
Operating lease liabilities, current and non-current				0
Deferred rent, non-current				1,468
Cash flows from financing activities:
Principal payments on finance leases				0
Principal payments on finance/capital leases and lease financing obligation				(720)
As Adjusted [Member]
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Depreciation and amortization				17,968
Amortization of finance lease right-of-use assets				1,004
Non-cash lease expense				7,536
Changes in operating assets and liabilities:
Prepaid expenses and other current assets				4,373
Accrued expenses and other current liabilities				(12,881)
Operating lease liabilities, current and non-current				(5,332)
Deferred rent, non-current				0
Cash flows from financing activities:
Principal payments on finance leases				(609)
Principal payments on finance/capital leases and lease financing obligation				0
Adjustments [Member]
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Depreciation and amortization				(1,128)
Amortization of finance lease right-of-use assets				1,004
Non-cash lease expense				7,536
Changes in operating assets and liabilities:
Prepaid expenses and other current assets				(600)
Accrued expenses and other current liabilities				(123)
Operating lease liabilities, current and non-current				(5,332)
Deferred rent, non-current				(1,468)
Cash flows from financing activities:
Principal payments on finance leases				(609)
Principal payments on finance/capital leases and lease financing obligation				$ 720
[1] As adjusted to reflect the impact of the adoption of Accounting Standards Codification Topic 842, Leases (“ASC 842”) as of January 1, 2022. See Note 1 for a summary of the adjustments.

Business Combination (Additiona

Business Combination (Additional Information) (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Business Acquisition [Line Items]
Common stock shares issued	2,093,440,000		2,031,883,000
FGen [Member]
Business Acquisition [Line Items]
Fair value of contingent consideration		$ 1,700
Restricted Stock [Member] | FGen [Member]
Business Acquisition [Line Items]
Contingent consideration of restricted stock	1,698,850
Shares forfeited		$ 584,246
Unrestricted Stock [Member] | FGen [Member]
Business Acquisition [Line Items]
Common stock shares issued	4,051,107
Business acquire consideration	$ 17,000
Business Acquisition, Share Price	$ 4.2
Common Class A [Member]
Business Acquisition [Line Items]
Common stock shares issued	1,595,167,000		1,448,234,000
Common Class A [Member] | FGen [Member]
Business Acquisition [Line Items]
Common stock shares issued	5,749,957

Business Combination - Summery

Business Combination - Summery Of Fair Value Of Contingent Consideration (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($)
Business Acquisition [Line Items]
Total Fgen consideration	$ 0
FGen AG [Member] | Milestone
Business Acquisition [Line Items]
Contingent consideration	8,464
FGen AG [Member] | Restricted Stock [Member]
Business Acquisition [Line Items]
Contingent consideration	3,842
Fgen
Business Acquisition [Line Items]
Total Fgen consideration	29,321
Fgen | Common Class A
Business Acquisition [Line Items]
Fair value of Class A common stock	$ 17,015

Business Combination - Summer_2

Business Combination - Summery of final allocation of the purchase price to the assets acquired and liabilities assumed (Details) - Fgen $ in Thousands	Jun. 30, 2023 USD ($)
Preliminary Allocation
Business Acquisition [Line Items]
Cash and cash equivalents	$ 1,430
Accounts receivable	144
Other non-current assets	10
Property and equipment	146
Intangible assets	21,100	[1]
Goodwill	11,001	[2]
Accounts payable and accrued expenses	(29)
Deferred revenue	(104)
Deferred tax liability	(4,377)
Net assets acquired	29,321
Measurement Period Adjustment
Business Acquisition [Line Items]
Accounts receivable	0	[3]
Other non-current assets	0	[3]
Property and equipment	(112)	[3]
Intangible assets	0	[1],[3]
Goodwill	(386)	[2],[3]
Accounts payable and accrued expenses	0	[3]
Deferred revenue	0	[3]
Deferred tax liability	498	[3]
Net assets acquired	0	[3]
Final Allocation
Business Acquisition [Line Items]
Cash and cash equivalents	1,430
Accounts receivable	144
Other non-current assets	10
Property and equipment	34
Intangible assets	21,100	[1]
Goodwill	10,615	[2]
Accounts payable and accrued expenses	(29)
Deferred revenue	(104)
Deferred tax liability	(3,879)
Net assets acquired	$ 29,321
[1] Estimated useful life of 15 years Non-deductible for tax purposes. Represents adjustments related to tangible assets acquired and estimated tax liabilities with a corresponding net decrease to goodwill.

Business Combination - Summer_3

Business Combination - Summery of final allocation of the purchase price to the assets acquired and liabilities assumed (Parenthetical) (Details)	Jun. 30, 2023
Asset Acquisition [Abstract]
Intangibles estimated useful life	15 years

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details) - USD ($) $ in Thousands		Jun. 30, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liabilities		$ 14,146	$ 10,868
Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets		1,126,335	1,154,337
Total liabilities		44,708	35,341
Fair Value, Recurring [Member] | Warrants [Member] | Synlogic, Inc. [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total included in investment	[1]	1,095	1,937
Fair Value, Recurring [Member] | Warrants [Member] | Marketable Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total included in investment		19,876	25,714	[2]
Fair Value, Recurring [Member] | Prepaid Expenses and Other Current Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Receivables, Fair Value Disclosure		358
Fair Value, Recurring [Member] | Other Noncurrent Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Receivables, Fair Value Disclosure		38,950	37,660
Fair Value, Recurring [Member] | Other Current Liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration		22,945	6,378
Fair Value, Recurring [Member] | Other Noncurrent Liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration, included in other non-current liabilities		7,617	18,095
Fair Value, Recurring [Member] | Money Market Funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total included in cash and cash equivalents		1,066,056	1,089,026
Fair Value, Recurring [Member] | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets		1,085,932	1,110,338
Total liabilities		8,970	6,900
Fair Value, Recurring [Member] | Level 1 | Marketable Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total included in investment	[2]		21,312
Fair Value, Recurring [Member] | Level 1 | Warrants [Member] | Synlogic, Inc. [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total included in investment	[1]	0	0
Fair Value, Recurring [Member] | Level 1 | Warrants [Member] | Marketable Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total included in investment		0
Fair Value, Recurring [Member] | Level 1 | Prepaid Expenses and Other Current Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Receivables, Fair Value Disclosure		0
Fair Value, Recurring [Member] | Level 1 | Other Noncurrent Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Receivables, Fair Value Disclosure		0	0
Fair Value, Recurring [Member] | Level 1 | Other Current Liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration		0	0
Fair Value, Recurring [Member] | Level 1 | Other Noncurrent Liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration, included in other non-current liabilities		0	0
Fair Value, Recurring [Member] | Level 1 | Money Market Funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total included in cash and cash equivalents		1,066,056	1,089,026
Fair Value, Recurring [Member] | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets		31,095	36,339
Total liabilities		141	108
Fair Value, Recurring [Member] | Level 2 | Marketable Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total included in investment	[2]		4,402
Fair Value, Recurring [Member] | Level 2 | Warrants [Member] | Synlogic, Inc. [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total included in investment	[1]	1,095	1,937
Fair Value, Recurring [Member] | Level 2 | Warrants [Member] | Marketable Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total included in investment		0
Fair Value, Recurring [Member] | Level 2 | Prepaid Expenses and Other Current Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Receivables, Fair Value Disclosure		0
Fair Value, Recurring [Member] | Level 2 | Other Noncurrent Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Receivables, Fair Value Disclosure		30,000	30,000
Fair Value, Recurring [Member] | Level 2 | Other Current Liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration		0	0
Fair Value, Recurring [Member] | Level 2 | Other Noncurrent Liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration, included in other non-current liabilities		0	0
Fair Value, Recurring [Member] | Level 2 | Money Market Funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total included in cash and cash equivalents		0	0
Fair Value, Recurring [Member] | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets		9,308	7,660
Total liabilities		35,597	28,333
Fair Value, Recurring [Member] | Level 3 | Marketable Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total included in investment	[2]		0
Fair Value, Recurring [Member] | Level 3 | Warrants [Member] | Synlogic, Inc. [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total included in investment	[1]	0	0
Fair Value, Recurring [Member] | Level 3 | Warrants [Member] | Marketable Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total included in investment		0
Fair Value, Recurring [Member] | Level 3 | Prepaid Expenses and Other Current Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Receivables, Fair Value Disclosure		358
Fair Value, Recurring [Member] | Level 3 | Other Noncurrent Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Receivables, Fair Value Disclosure		8,950	7,660
Fair Value, Recurring [Member] | Level 3 | Other Current Liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration		22,945	6,378
Fair Value, Recurring [Member] | Level 3 | Other Noncurrent Liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration, included in other non-current liabilities		7,617	18,095
Fair Value, Recurring [Member] | Level 3 | Money Market Funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total included in cash and cash equivalents		0	0
Private Placement Warrants [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liabilities	[3]	5,176	3,968
Private Placement Warrants [Member] | Fair Value, Recurring [Member] | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liabilities	[3]	0	0
Private Placement Warrants [Member] | Fair Value, Recurring [Member] | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liabilities	[3]	141	108
Private Placement Warrants [Member] | Fair Value, Recurring [Member] | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liabilities	[3]	5,035	3,860
Public Warrants [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liabilities		8,970	6,900
Public Warrants [Member] | Fair Value, Recurring [Member] | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liabilities		8,970	6,900
Public Warrants [Member] | Fair Value, Recurring [Member] | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liabilities		0	0
Public Warrants [Member] | Fair Value, Recurring [Member] | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liabilities		$ 0	$ 0
[1] (1) The fair value of Synlogic, Inc. warrants is calculated as the quoted price of the underlying common stock, less the unpaid exercise price of the warrants. (2) Marketable equity securities classified as Level 2 reflect a discount for lack of marketability due to regulatory sales restrictions. (3) The fair value of Private Placement Warrants classified as Level 2 is equivalent to that of Public Warrants as the transfer of Private Placement Warrants to anyone other than the initial purchasers or any of their permitted transferees results in the Private Placement Warrants having substantially the same terms as the Public Warrants.

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended			12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022		Dec. 31, 2022	Sep. 16, 2021
Asset Impairment Charges			$ 1,800
Risk Free Interest Rate			3.94%	3.25%
prepayment from customers	$ 80,568	$ 144,618	$ 161,270	$ 313,023	[1]
Maximum [Member]
Debt Instrument, term			2 years			3 years
Minimum [Member]
Debt Instrument, term			1 year			1 year
SAFEs [Member]
Asset Impairment Charges		$ 0	$ 1,800	$ 0
Discount Rate	14%		14%
SAFEs [Member] | Maximum [Member]
Probabilities rate			85%
SAFEs [Member] | Minimum [Member]
Probabilities rate			15%
Promissory Note [Member]
Unpaid Principal Amount	$ 11,700		$ 11,700			$ 7,500
Fair Value Of Promissory Note	$ 9,300		$ 9,300			7,700
Level 3
Discount Rate	14%		14%
Level 3 | Maximum [Member]
Probabilities rate			60%
Debt Instrument, term			2 years
Level 3 | Minimum [Member]
Probabilities rate			20%
Debt Instrument, term			1 year
Level 3 | Public Warrants [Member]
Assumed Class Of Warrant Or Right Outstanding							34.5
Level 3 | Private Placement Warrants [Member]
Assumed Class Of Warrant Or Right Outstanding							17.3
Bolt Threads, Inc. [Member] | Senior Secured Note [Member]
Notes receivable fair value recurring basis	$ 30,000		$ 30,000			$ 30,000
Dutch Dna Biotech BV [Member]
Contingent consideration, included in other non-current liabilities	20,000		20,000
Circularis Biotechnologies, Inc [Member]
Payment for achievement of a technical development milestone			40,000
Circularis Biotechnologies, Inc [Member] | Restricted Stock [Member]
Loss On Fair Value Of Contigent Consideration	1,400		1,400
Contingent consideration, included in other non-current liabilities	3,800		3,800
Cash and cash equivalents	$ 1,500		$ 1,500
Contingent consideration liabilities, Vest Shares	1.2		1.2
Contingent consideration liabilities, Vest Value	$ 2,300		$ 2,300
Altar SAS [Member]
Payment for achievement of a technical development milestone			2,500
FGen AG [Member]
Contingent consideration, included in other non-current liabilities	20,000		20,000
SAFE [Member]
prepayment from customers			11,000
Fair value of customers obligations	$ 4,500		$ 4,500
Notes Receivable
Discount Rate						12.50%
Notes Receivable | Maximum [Member]
Probabilities rate			55%			55%
Notes Receivable | Minimum [Member]
Probabilities rate			15%			15%
Discount Rate	17%		17%
[1] As adjusted to reflect the impact of the adoption of Accounting Standards Codification Topic 842, Leases (“ASC 842”) as of January 1, 2022. See Note 1 for a summary of the adjustments.

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Change in the Fair Value of the Warrant Liabilities (Details) - Fair Value, Inputs, Level 3 [Member] - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Contingent Consideration [Member]
Schedule Of Changes In The Fair Value Of Warrant Liabilities [Line Items]
Change in fair value	$ 8,453	$ 300
Notes Receivable [Member]
Schedule Of Changes In The Fair Value Of Warrant Liabilities [Line Items]
Notes Receivable Beginning Balance	7,660	11,559
Change in fair value	3,137	0
Change in fair value	(1,489)	(292)
Notes Receivable Ending Balance	9,308	11,267
Private Placement Warrants [Member]
Schedule Of Changes In The Fair Value Of Warrant Liabilities [Line Items]
Change in fair value	$ 1,175	$ (49,549)

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Fair Value Measurements Inputs (Detail) - Fair Value, Inputs, Level 3 [Member]	Jun. 30, 2023	Dec. 31, 2022
Measurement Input, Exercise Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurements inputs	11.5	11.5
Measurement Input, Share Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurements inputs	1.86	1.69
Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurements inputs	79	71.5
Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurements inputs	3.21	3.71
Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurements inputs	4.49	4.11

Fair Value Measurement - Summer

Fair Value Measurement - Summery Of fair value of the Reconcilliation Of The Private Placements Of Warrants (Details) - Level 3 - Private Placement Warrants [Member] - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Beginning balance warrant liabilities	$ 3,860	$ 58,558
Change in fair value	1,175	(49,549)
Ending balance warrant liabilities	$ 5,035	$ 9,009

Fair Value Measurement - Schedu

Fair Value Measurement - Schedule Of fair value measurements of contingent consideration liabilities (Details) - Fair Value, Recurring [Member]	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Valuation Technique, Discounted Cash Flow [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Discount Rate	11.50%	12%
Maximum [Member] | Probability-weighted present value [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Discount Rate	95%	100%
Maximum [Member] | Valuation Technique, Discounted Cash Flow [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Discount Rate	14.60%	13.10%
Projected years of payments	2028 years	2028 years
Minimum [Member] | Probability-weighted present value [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Discount Rate	1%	2%
Minimum [Member] | Valuation Technique, Discounted Cash Flow [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Discount Rate	13.50%	12.20%
Projected years of payments	2025 years	2025 years

Fair Value Measurement - Sche_2

Fair Value Measurement - Schedule Of Reconciliation Of The Contingent Consideration Measured At Fair Value Using Level 3 Significant Unobservable Inputs (Details) - Contingent Consideration [Member] - Level 3 - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Beginning balance warrant liabilities	$ 24,473	$ 8,467
Additions	0	12,306
Change in fair value	8,453	300
Settlements and payments	(2,364)	(2,644)
Ending balance warrant liabilities	$ 30,562	$ 18,429

Investments and Equity Method_3

Investments and Equity Method Investments (Additional Information) (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Net Investment Income [Line Items]
Impairment loss		$ 1.8
Genomatica Inc Preferred Stocks [Member]
Net Investment Income [Line Items]
Impairment loss			$ 10.1
SAFEs [Member]
Net Investment Income [Line Items]
Impairment loss	$ 0	$ 1.8	$ 0

Investments and Equity Method_4

Investments and Equity Method Investments - Schedule of Investments and Equity Method Investments (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022		Dec. 31, 2022
Net Investment Income [Line Items]
Investments		$ 119,944		$ 119,944			$ 112,188
Equity Method Investments	[1]	1,120		1,120			1,543
Loss on investments		(2,121)	$ (38,673)	(8,491)	$ (38,223)	[2]
Income (Loss) from Equity Method Investments, Total		(67)	(10,166)	(1,516)	(31,053)	[2]
Genomatica, Inc. Preferred Stock [Member]
Net Investment Income [Line Items]
Investments		44,885		44,885			44,885
Synlogic, Inc. Common Stock [Member]
Net Investment Income [Line Items]
Investments		2,727		2,727			4,819
Loss on investments		(1,281)	(7,926)	(2,092)	(8,053)
Synlogic, Inc. Warrant [Member]
Net Investment Income [Line Items]
Investments		1,095		1,095			1,937
Loss on investments		(514)	(3,185)	(841)	(3,236)
Marketable Equity Securities [Member]
Net Investment Income [Line Items]
Investments		17,149		17,149			20,895
Loss on investments		(326)	(17,447)	(3,747)	(16,819)
Non Marketable Equity Securities [Member]
Net Investment Income [Line Items]
Investments		29,259		29,259			17,544
SAFEs [Member]
Net Investment Income [Line Items]
Investments		24,829		24,829			22,108
Loss on investments		0	0	(1,811)	0
BiomEdit LLC [Member]
Net Investment Income [Line Items]
Equity Method Investments	[1]	0		0			369
Income (Loss) from Equity Method Investments, Total		0	(4,552)	(1,462)	(4,552)
Joyn Bio, LLC [Member]
Net Investment Income [Line Items]
Income (Loss) from Equity Method Investments, Total		0	(5,424)	0	(10,411)
Verb Biotics LLC Member
Net Investment Income [Line Items]
Income (Loss) from Equity Method Investments, Total		0	0	0	(15,900)
Other [Member]
Net Investment Income [Line Items]
Equity Method Investments	[1]	1,120		1,120			$ 1,174
Income (Loss) from Equity Method Investments, Total		(67)	(190)	(54)	(190)
Genomatica [Member]
Net Investment Income [Line Items]
Loss on investments		$ 0	$ (10,115)	$ 0	$ (10,115)
[1] Equity method investments in Platform Ventures with a carrying value of zero as of June 30, 2023 and December 31, 2022 were excluded from the table. As adjusted to reflect the impact of the adoption of Accounting Standards Codification Topic 842, Leases (“ASC 842”) as of January 1, 2022. See Note 1 for a summary of the adjustments.

Investments and Equity Method_5

Investments and Equity Method Investments - Schedule of Investments and Equity Method Investments (Parenthetical) (Details) - USD ($) $ in Thousands		Jun. 30, 2023	Dec. 31, 2022
Net Investment Income [Line Items]
Equity Method Investments	[1]	$ 1,120	$ 1,543
Platform Ventures Member
Net Investment Income [Line Items]
Equity Method Investments		$ 0	$ 0
[1] Equity method investments in Platform Ventures with a carrying value of zero as of June 30, 2023 and December 31, 2022 were excluded from the table.

Variable Interest Entities (Add

Variable Interest Entities (Additional Information) (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	[1]
Variable Interest Entity [Line Items]
Gain on deconsolidation of subsidiary	$ 0	$ 0		$ 0	$ 15,900
Ginkgo [Member]
Variable Interest Entity [Line Items]
Gain on deconsolidation of subsidiary			$ 15,900
Cooksonia
Variable Interest Entity [Line Items]
Controls of Board of Directors				100%
[1] As adjusted to reflect the impact of the adoption of Accounting Standards Codification Topic 842, Leases (“ASC 842”) as of January 1, 2022. See Note 1 for a summary of the adjustments.

Supplemental Financial Inform_3

Supplemental Financial Information (Additional Information) (Details) - USD ($) $ in Thousands, shares in Millions			3 Months Ended	6 Months Ended
	May 09, 2023	Apr. 03, 2023	Jun. 30, 2023	Jun. 30, 2023	Dec. 31, 2022
Supplemental Financial Information [Line Items]
Property, plant, and equipment, net			$ 294,244	$ 294,244	$ 314,773
Common Class A
Supplemental Financial Information [Line Items]
Common stock shares issued for acquisition		2.8
Common stock issued for employee retention payments, shares	2
Common stock issued for employee retention payments	$ 2,500
Lab Equipment [Member]
Supplemental Financial Information [Line Items]
Impairment of equipment			9,000	9,000
Assets book value written down to fair value				14,900
Property, plant, and equipment, net			$ 4,200	$ 4,200

Supplemental Financial Inform_4

Supplemental Financial Information - Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands		Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Restricted Cash and Cash Equivalents [Abstract]
Cash and cash equivalents		$ 1,105,787	$ 1,315,792	$ 1,377,152	$ 1,550,004
Restricted cash included in other non-current assets	[1]	22,483		4,239
Restricted cash included in other non-current assets	[1]	43,791		39,444
Total cash, cash equivalents and restricted cash		$ 1,172,061	$ 1,369,581	$ 1,420,835	$ 1,592,928
[1] (1) I ncludes cash balances collateralizing letters of credit associated with the Company’s facility leases and a customer prepayment requiring segregation and restrictions in its use in accordance with the customer agreement.

Supplemental Financial Inform_5

Supplemental Financial Information - Schedule of Inventory, Net (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Finished goods	$ 4,435	$ 6,556
Raw materials	0	1,590
Less: inventory reserve	(4,949)	(3,782)
Inventory, net	$ 391	$ 4,364

Supplemental Financial Inform_6

Supplemental Financial Information - Summary of Property and Equipment, Net (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	$ 412,714	$ 407,529
Less: Accumulated depreciation	(118,470)	(92,756)
Property and equipment, net	294,244	314,773
Lab Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	180,025	183,292
Property and equipment, net	4,200
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	136,197	125,307
Buildings and facilities [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	46,927	46,019
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	19,831	23,426
Computer equipment and software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	15,322	15,219
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	8,352	8,206
Land [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	$ 6,060	$ 6,060

Supplemental Financial Inform_7

Supplemental Financial Information - Capitalization (Details) - shares	Jun. 30, 2023	Dec. 31, 2022
Common Stock, Shares Authorized	15,800,000,000	15,800,000,000
Common Stock, Shares, Issued	2,093,440,000	2,031,883,000
Common Stock, Shares, Outstanding	1,954,704,000	1,891,976,000
Common Class A [Member]
Common Stock, Shares Authorized	10,500,000,000	10,500,000,000
Common Stock, Shares, Issued	1,595,167,000	1,448,234,000
Common Stock, Shares, Outstanding	1,478,611,000	1,337,499,000
Common Class B [Member]
Common Stock, Shares Authorized	4,500,000,000	4,500,000,000
Common Stock, Shares, Issued	378,273,000	383,649,000
Common Stock, Shares, Outstanding	356,093,000	354,477,000
Common Class C [Member]
Common Stock, Shares Authorized	800,000,000	800,000,000
Common Stock, Shares, Issued	120,000,000	200,000,000
Common Stock, Shares, Outstanding	120,000,000	200,000,000

Supplemental Financial Inform_8

Supplemental Financial Information - Schedule of Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands		6 Months Ended
		Jun. 30, 2023	Jun. 30, 2022
ROU assets obtained in exchange for new operating lease liabilities upon adoption of ASC 842		$ 0
ROU assets obtained in exchange for new finance lease liabilities upon adoption of ASC 842		0
ROU asset obtained in exchange for new operating lease liabilities		13,649
ROU Asset obtained in exchange for new finance lease liabilities		0
Purchases of property and equipment included in accounts payable and accrued expenses		2,324
Equity received in related parties		0
Convertible financial instruments received for Cell Engineering services		5,595
Equity securities and warrants received for Cell Engineering services		12,493
Settlement of contingent consideration - restricted stock		2,262
Common stock issued for business and asset acquisitions		3,581
Contingent consideration for business acquisition		$ 0
As Adjusted [Member]
ROU assets obtained in exchange for new operating lease liabilities upon adoption of ASC 842	[1]		$ 147,744
ROU assets obtained in exchange for new finance lease liabilities upon adoption of ASC 842	[1]		3,397
ROU asset obtained in exchange for new operating lease liabilities	[1]		28,000
ROU Asset obtained in exchange for new finance lease liabilities	[1]		1,096
Purchases of property and equipment included in accounts payable and accrued expenses	[1]		6,741
Equity received in related parties	[1]		8,873
Convertible financial instruments received for Cell Engineering services	[1]		11,939
Equity securities and warrants received for Cell Engineering services	[1]		3,423
Settlement of contingent consideration - restricted stock	[1]		0
Common stock issued for business and asset acquisitions	[1]		17,015
Contingent consideration for business acquisition	[1]		$ 12,306
[1] * As adjusted to reflect the impact of the adoption of ASC 842 as of January 1, 2022. See Note 1 for a summary of the adjustments.

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets, net - Schedule of Goodwill (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Beginning balance	$ 60,210
Impact of foreign currency translation	592
Measurement period adjustments	(1,973)
Ending balance	$ 58,829

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets, net - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands		6 Months Ended	12 Months Ended
		Jun. 30, 2023	Dec. 31, 2022
Acquired Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	[1]	$ 122,404	$ 120,094
Accumulated Amortization	[1]	(17,371)	(9,053)
Total		105,033	111,041
Developed Technology [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	[1]	118,134	115,824
Accumulated Amortization	[1]	(16,717)	(8,825)
Total		$ 101,417	$ 106,999
Weighted Average Amortization Period		9 years	9 years 4 months 24 days
Database [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	[1]	$ 3,700	$ 3,700
Accumulated Amortization	[1]	(371)	(107)
Total		$ 3,329	$ 3,593
Weighted Average Amortization Period		6 years 3 months 18 days	6 years 9 months 18 days
Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	[1]	$ 380	$ 380
Accumulated Amortization	[1]	(166)	(71)
Total		$ 214	$ 309
Weighted Average Amortization Period		1 year 1 month 6 days	1 year 7 months 6 days
Assembled Workforce [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	[1]	$ 190	$ 190
Accumulated Amortization	[1]	(117)	(50)
Total		$ 73	$ 140
Weighted Average Amortization Period		6 months	1 year
[1] (1) Gross carrying value and accumulated amortization include the impact of cumulative foreign currency translation adjustments.

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets, net - Schedule of Amortization expense (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of 2023	$ 7,911
2024	15,630
2025	15,505
2026	15,505
2027	12,431
Thereafter	38,051
Total	$ 105,033	$ 111,041

Goodwill and Intangible Asset_6

Goodwill and Intangible Assets, net - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Goodwill [Line Items]
Amortization expense	$ 4,000	$ 800	$ 8,300	$ 1,300
Decrease to goodwill			2,200
Increase to accounts receivable			1,800
Decrease in other current liabilities			400
Goodwill	58,829		58,829		$ 60,210
Altar SAS acquisition
Goodwill [Line Items]
Goodwill	$ 200		$ 200

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) $ in Thousands		3 Months Ended		6 Months Ended
	Apr. 05, 2023 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	[1]	Mar. 31, 2022 USD ($)
Loss Contingencies [Line Items]
Research and Development Expense		$ 144,282	$ 290,059	$ 306,921	$ 613,635
Year Two [Member] | Twist Bioscience Corporation [Member]
Loss Contingencies [Line Items]
Minimum purchase commitment in contract years							$ 13,000
Year Three [Member] | Twist Bioscience Corporation [Member]
Loss Contingencies [Line Items]
Minimum purchase commitment in contract years							16,000
Year Four [Member] | Twist Bioscience Corporation [Member]
Loss Contingencies [Line Items]
Minimum purchase commitment in contract years							$ 19,000
Asset Purchase Agreement [Member] | StrideBio [Member]
Loss Contingencies [Line Items]
Payments for Royalties		$ 0		0
Royalty Recived From License Or Sale Of a Product	40
Royalty Recived From Licensing Revenue	10
Asset Purchase Agreement [Member] | Common Class A [Member] | StrideBio [Member]
Loss Contingencies [Line Items]
Additional consideration	$ 7,500
Fair value of the assets				2,800
Payments for Royalties	$ 17,500
Common Stock [Member] | Asset Purchase Agreement [Member] | StrideBio [Member]
Loss Contingencies [Line Items]
Fair value of the assets				4,000
Research and Development Expense				400
Common Stock [Member] | Asset Purchase Agreement [Member] | Common Class A [Member] | StrideBio [Member]
Loss Contingencies [Line Items]
Research and Development Expense				$ 3,600
[1] As adjusted to reflect the impact of the adoption of Accounting Standards Codification Topic 842, Leases (“ASC 842”) as of January 1, 2022. See Note 1 for a summary of the adjustments.

Stock-Based Compensation - Cond

Stock-Based Compensation - Condensed Consolidated Statements of Operations and Comprehensive Loss (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 61,488	$ 606,515	$ 134,474	$ 1,259,336
Research and Development [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	39,927	216,838	86,427	477,846
General and Administrative [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 21,561	$ 389,677	$ 48,047	$ 781,490

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands		6 Months Ended
	Sep. 16, 2021	Jun. 30, 2023	Jun. 30, 2022	Nov. 15, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Aggregate intrinsic value of stock options exercised		$ 2,900	$ 9,100
Options with an aggregate fair value		$ 1,400	$ 1,200
Options, grants in period, weighted average grant date fair value		$ 1.43	$ 1.84
Stock-based compensation		$ 134,474	$ 1,259,336
Earn-Out Shares [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized compensation expense		$ 9,900
Unrecognized stock-based compensation recognition period		1 year 8 months 12 days
Earn-Out Shares [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award vesting period	30 days
Earn-Out Shares [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award vesting period	20 days
Non-Employee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Cash Payment in Plan Modification			9,800
Stock Options [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized compensation expense		$ 1,800
Unrecognized stock-based compensation recognition period		1 year 2 months 12 days
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period		27,217,000
No of awards granted		88,869,000
Cash Payment in Plan Modification			$ 3,200
Options, grants in period, weighted average grant date fair value		$ 1.32	$ 3.79
Fair value of restricted stock awards vested		$ 185,900	$ 199,300
Unrecognized compensation expense		$ 413,600
Unrecognized stock-based compensation recognition period		3 years 2 months 12 days
RSA [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period		4,000
No of awards granted		0	0
Earnout RSU [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period		307,000
Fair value of restricted stock awards vested		$ 4,100	$ 5,800
Share-Based Payment Arrangement, Tranche One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share price				$ 12.5
Share-Based Payment Arrangement, Tranche One [Member] | Common Stock [Member] | Earn-Out Shares [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share price	$ 12.5
Share-Based Payment Arrangement, Tranche Two [Member] | Common Stock [Member] | Earn-Out Shares [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share price	15
Share-Based Payment Arrangement, Tranche Three [Member] | Common Stock [Member] | Earn-Out Shares [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share price	17.5
Share Based Compensation Award Tranche Four Member | Common Stock [Member] | Earn-Out Shares [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share price	$ 20
2021 Incentive Award Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock reserved for issuance		187,900,000
2022 Inducement Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock reserved for issuance		8,300,000

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activity (Details) $ / shares in Units, shares in Thousands, $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($) $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares , Beginning balance | shares	10,501	[1]
Number of shares, Granted | shares	979	[1]
Number of shares, Exercised | shares	(1,572)	[1]
Number of shares, Ending balance | shares	9,908	[1]
Number of shares, Exercisable | shares	8,707	[1]
Weighted average exercise price per share, Beginning balance | $ / shares	$ 0.34
Weighted average exercise price per share, Granted | $ / shares	1.9
Weighted-average exercise price per share, Exercised | $ / shares	0.01
Weighted average exercise price per share, Ending balance | $ / shares	0.55
Weighted-average exercise price per share, Exercisable | $ / shares	$ 0.3
Weighted-average remaining contractual term, Outstanding	2 years 6 months 18 days
Weighted-average remaining contractual term, Exercisable	1 year 6 months 21 days
Aggregate intrinsic value, Outstanding | $	$ 14,614	[2]
Aggregate intrinsic value, Exercisable | $	$ 14,614	[2]
[1] Excludes 1.9 million shares underlying options issued outside the accounting for compensation awards under ASC 718. The aggregate intrinsic value is calculated as the difference between the Company's closing stock price on the last trading day of the quarter and the exercise prices, multiplied by the number of in-the-money stock options.

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Stock Option Activity (Parenthetical) (Details) shares in Millions	Jun. 30, 2023 shares
Share-Based Payment Arrangement [Abstract]
Underlying options issued	1.9

Stock-Based Compensation - Key

Stock-Based Compensation - Key input assumptions in the Black-Scholes option-pricing model (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Risk Free Interest Rate	3.94%	3.25%
Expected volatility	93%	75%
Expected term (in years)	5 years 6 months	5 years 6 months
Dividend yield	$ 0	$ 0

Stock-Based Compensation - Shar

Stock-Based Compensation - Share-based Payment Arrangement, Restricted Stock Unit, Activity (Details) - $ / shares	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
RSU Activity [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Number of shares, Nonvested at beginning of period (in shares)	134,436,000
Number of share, Granted	88,869,000
Number of share, Vested	(27,217,000)
Number of Share Forfeited	(11,852,000)
Number of shares, Nonvested at end of period (in shares)	184,236,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted average grant date fair value, Nonvested at beginning of period	$ 5.84
Weighted average grant date fair value, Granted	1.32
Weighted average grant date fair value, Vested	6.83
Weighted average grant date fair value, Forfeited	4.24
Weighted average grant date fair value, Nonvested at end of period	$ 3.61
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Number of shares, Nonvested at beginning of period (in shares)	4,000
Number of share, Granted	0	0
Number of share, Vested	(4,000)
Number of shares, Nonvested at end of period (in shares)	0
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted average grant date fair value, Nonvested at beginning of period	$ 1.99
Weighted average grant date fair value, Vested	1.99
Weighted average grant date fair value, Nonvested at end of period	$ 0

Stock-Based Compensation - Su_3

Stock-Based Compensation - Summary of Restricted Stock Awards (Details) - Earnout RSU [Member] shares in Thousands	6 Months Ended
	Jun. 30, 2023 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Number of shares, Nonvested at beginning of period (in shares) | shares	23,520
Number of share, Vested | shares	(307)
Number of Share Forfeited | shares	(241)
Number of shares, Nonvested at end of period (in shares) | shares	22,972
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted average grant date fair value, Nonvested at beginning of period | $ / shares	$ 12.79
Weighted average grant date fair value, Vested | $ / shares	13.34
Weighted average grant date fair value, Forfeited | $ / shares	12.25
Weighted average grant date fair value, Nonvested at end of period | $ / shares	$ 12.79

Revenue Recognition - Disaggreg

Revenue Recognition - Disaggregation of Revenue (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Disaggregation of Revenue [Line Items]
Total Cell Engineering revenue	100%	100%	100%	100%
Pharma and Biotech
Disaggregation of Revenue [Line Items]
Total Cell Engineering revenue	40%	15%	35%	16%
Agriculture
Disaggregation of Revenue [Line Items]
Total Cell Engineering revenue	20%	4%	23%	4%
Customer And Technology
Disaggregation of Revenue [Line Items]
Total Cell Engineering revenue	14%	61%	12%	52%
Food And Nutrition
Disaggregation of Revenue [Line Items]
Total Cell Engineering revenue	11%	9%	13%	9%
Industrial And Environment
Disaggregation of Revenue [Line Items]
Total Cell Engineering revenue	11%	8%	12%	16%
Government and Defense [Member]
Disaggregation of Revenue [Line Items]
Total Cell Engineering revenue	4%	3%	5%	3%

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Contract asset	$ 0		$ 0		$ 0
Contract with Customer, Liability, Revenue Recognized			$ 44,100	$ 25,200
Contract liabilities					$ 222,600	$ 189,200
UNITED STATES | Customer Concentration Risk [Member]
Disaggregation of Revenue [Line Items]
Total revenue	84%	82%	84%	91%

Revenue Recognition - Additio_2

Revenue Recognition - Additional Information 1 (Details) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue Remaining Performance Obligation	$ 115.1	$ 123.5
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue remaining performance obligation expected timing of satisfaction year	2023
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue remaining performance obligation expected timing of satisfaction year	2027

Segment Information Schedule of

Segment Information Schedule of Segment Reporting Information, by Segment (Details) - USD ($) $ in Thousands		3 Months Ended			6 Months Ended
		Jun. 30, 2023	Jun. 30, 2022		Jun. 30, 2023	Jun. 30, 2022
Segment research and development expense:
Research and development		$ 144,282	$ 290,059		$ 306,921	$ 613,635	[1]
Operating expenses not allocated to segments abstract
Stock-based compensation					134,474	1,259,336
Depreciation and amortization					36,610	17,968
Asset impairment					1,800
Loss from operations		(184,151)	(647,779)		(399,896)	(1,323,150)	[1]
CODM [Member]
Revenue:
Revenues		80,568	144,618	[2]	161,270	313,023	[2]
Segment research and development expense:
Research and development		86,611	64,391	[2]	185,700	113,319	[2]
Segment general and administrative expense:
Segment general and administrative expense		67,606	49,010	[2]	143,254	88,938	[2]
Segment operating income (loss):
Total segment operating income (loss)		(91,745)	(32,694)	[2]	(208,155)	(38,577)	[2]
Operating expenses not allocated to segments abstract
Stock-based compensation	[3]	62,477	607,270	[2]	137,677	1,266,305	[2]
Depreciation and amortization		17,652	9,028	[2]	36,610	17,968	[2]
Asset impairment		9,001	0	[2]	9,001	0	[2]
Change in fair value of contingent consideration liability		3,276	(1,213)	[2]	8,453	300	[2]
Loss from operations		(184,151)	(647,779)	[2]	(399,896)	(1,323,150)	[2]
Biosecurity | CODM [Member]
Revenue:
Revenues		35,285	100,376	[2]	81,891	247,293	[2]
Segment cost of revenue:
Cost of revenue		18,096	63,911	[2]	40,471	149,343	[2]
Segment research and development expense:
Research and development		528	443	[2]	1,095	960	[2]
Segment general and administrative expense:
Segment general and administrative expense		16,699	12,409	[2]	30,655	25,644	[2]
Segment operating income (loss):
Total segment operating income (loss)		(38)	23,613	[2]	9,670	71,346	[2]
Cell Engineering revenue [Member] | CODM [Member]
Revenue:
Revenues		45,283	44,242	[2]	79,379	65,730	[2]
Segment research and development expense:
Research and development		86,083	63,948	[2]	184,605	112,359	[2]
Segment general and administrative expense:
Segment general and administrative expense		50,907	36,601	[2]	112,599	63,294	[2]
Segment operating income (loss):
Total segment operating income (loss)		$ (91,707)	$ (56,307)	[2]	$ (217,825)	$ (109,923)	[2]
[1] As adjusted to reflect the impact of the adoption of Accounting Standards Codification Topic 842, Leases (“ASC 842”) as of January 1, 2022. See Note 1 for a summary of the adjustments. * As adjusted to reflect the impact of the adoption of ASC 842 as of January 1, 2022. See Note 1 for a summary of the adjustments. (1) Includes $ 1.0 million and $ 0.8 million in employer payroll taxes for the three months ended June 30, 2023 and 2022 , respectively, and $ 3.2 million and $ 7.0 million in employer payroll taxes for the six months ended June 30, 2023 and 2022, respectively.

Segment Information - Schedule

Segment Information - Schedule of Segment Reporting Information, by Segment (Parenthetical) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Segment Reporting [Abstract]
Employer payroll taxes	$ 1	$ 0.8	$ 3.2	$ 7

Significant Collaboration Tra_2

Significant Collaboration Transactions - Additional Information (Details) - USD ($) $ in Thousands, shares in Millions	1 Months Ended	3 Months Ended			6 Months Ended
	Apr. 30, 2022	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	[1]	Dec. 31, 2022
Business Acquisition [Line Items]
Consideration					$ 0
Income (Loss) from Equity Method Investments		$ (67)		$ (10,166)	(1,516)	$ (31,053)
Deferred revenue (includes $2,672 and $10,309 from related parties)		133,779			133,779			$ 141,497
Revenue, Remaining Performance Obligation, Amount		$ 115,100			$ 115,100			123,500
BiomEdit LLC [Member]
Business Acquisition [Line Items]
Consideration	$ 32,500		$ 4,000
Common units	3.9	0.7			0.7
Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited	0.7		0.3
Carrying value of the equity method investment					$ 8,900
Allocated upfront non-cash consideration					2,200
Deferred revenue (includes $2,672 and $10,309 from related parties)		$ 7,900			7,900			$ 8,100
Deferred revenue, Revenue recognized		900			1,800
Additional preferred units issued			0.8
Additional non-cash consideration			$ 1,100
Revenue, Remaining Performance Obligation, Amount		$ 300			300
common unit retained			0.4
Series A Preferred Stock | BiomEdit LLC [Member]
Business Acquisition [Line Items]
Share Sold	6.7
Additional share	1.5
Income (Loss) from Equity Method Investments					$ 1,500
Allocated upfront non-cash consideration			$ 1,100
Additional preferred units issued	1.5
[1] As adjusted to reflect the impact of the adoption of Accounting Standards Codification Topic 842, Leases (“ASC 842”) as of January 1, 2022. See Note 1 for a summary of the adjustments.

Net Loss per Share - Schedule o

Net Loss per Share - Schedule of Earnings Per Share, Basic and Diluted (Details) (Details) - $ / shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	[1]
Denominator
Weighted average common shares outstanding, basic	1,933,437	1,620,704	1,924,251	1,614,138
Effect of dilutive securities:
Weighted average common shares outstanding, diluted	1,933,437	1,620,704	1,924,251	1,614,138
Basic	$ (0.09)	$ (0.41)	$ (0.2)	$ (0.78)
Diluted	$ (0.09)	$ (0.41)	$ (0.2)	$ (0.78)
[1] As adjusted to reflect the impact of the adoption of Accounting Standards Codification Topic 842, Leases (“ASC 842”) as of January 1, 2022. See Note 1 for a summary of the adjustments.

Net Loss per Share - Summary Of

Net Loss per Share - Summary Of Anti-Dilutive Shares (Details) - shares		6 Months Ended
		Jun. 30, 2023	Jun. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded from the computation of diluted loss per share		400,175	448,164
Warrants [Member] | Class A common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded from the computation of diluted loss per share		51,825	51,825
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded from the computation of diluted loss per share		11,796	21,453
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded from the computation of diluted loss per share		184,236	214,272
Unvested RSAs [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded from the computation of diluted loss per share		0	93
Earnout shares [Member] | Class A common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded from the computation of diluted loss per share	[1]	152,318	160,521
[1] Represents earnout shares for which the service-based vesting conditions and/or market conditions have not been met.

Related Parties - Summary of Co

Related Parties - Summary of Condensed Consolidated Balance Sheets (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Related Party Transaction [Line Items]
Accounts receivable - related parties	$ 899	$ 1,558
Deferred revenue (includes $2,672 and $10,309 from related parties)	133,779	141,497
Motif [Member]
Related Party Transaction [Line Items]
Deferred revenue (includes $2,672 and $10,309 from related parties)	51,996	52,018
Genomatica [Member]
Related Party Transaction [Line Items]
Deferred revenue (includes $2,672 and $10,309 from related parties)	4,262	6,250
Allonnia [Member]
Related Party Transaction [Line Items]
Accounts receivable - related parties	228	140
Deferred revenue (includes $2,672 and $10,309 from related parties)	35,853	35,876
Arcaea [Member]
Related Party Transaction [Line Items]
Accounts receivable - related parties	68	335
Deferred revenue (includes $2,672 and $10,309 from related parties)	33,226	38,334
Verb [Member]
Related Party Transaction [Line Items]
Accounts receivable - related parties	285	361
Ayana [Member]
Related Party Transaction [Line Items]
Accounts receivable - related parties	202	403
BiomEdit [Member]
Related Party Transaction [Line Items]
Accounts receivable - related parties	116	288
Deferred revenue (includes $2,672 and $10,309 from related parties)	7,947	8,144
Other Equity Investess [Member]
Related Party Transaction [Line Items]
Accounts receivable - related parties	0	31
Deferred revenue (includes $2,672 and $10,309 from related parties)	$ 495	$ 875

Related Parties - Summary of _2

Related Parties - Summary of Condensed Consolidated Statements of Operations and Comprehensive Loss (Details) - Related Party [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Related Party Transaction [Line Items]
Revenues	$ 6,507	$ 7,973	$ 11,212	$ 21,501
Joyn [Member]
Related Party Transaction [Line Items]
Revenues	0	947	0	2,129
Motif [Member]
Related Party Transaction [Line Items]
Revenues	2	507	3	1,852
Genomatica [Member]
Related Party Transaction [Line Items]
Revenues	779	2,405	1,988	5,763
Allonnia [Member]
Related Party Transaction [Line Items]
Revenues	159	439	245	3,660
Arcaea [Member]
Related Party Transaction [Line Items]
Revenues	4,234	2,363	5,696	6,287
Verb [Member]
Related Party Transaction [Line Items]
Revenues	81	639	518	938
Ayana [Member]
Related Party Transaction [Line Items]
Revenues	184	0	636	0
BiomEdit [Member]
Related Party Transaction [Line Items]
Revenues	869	0	1,777	0
Other equity investees [Member]
Related Party Transaction [Line Items]
Revenues	$ 199	$ 673	$ 349	$ 872